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ABSTRACT OF THE THESIS
MODIFICATION OF A NOVEL POLYMER WITH POTENTIAL USE IN
ARTIFICIAL HEART VALVES: EFFECTS ON HEMOCOMPATIBILITY AND
MECHANICAL PROPERTIES
by
Tejas Dilipku mar Choksi
Florida International University, 2004
Miami, Florida
Professor Richard T. Schoephoerster, Major Professor
Platelet mediated thrombosis has been a major source of mortality and morbidity in
cardiovascular device patients as the device surface upon contact with blood induces
surface thrombosis. Two specific objectives of this thesis are: 1) Identify the effect of
phospholipid

modification

on Quatromer and 2) Identify the most effective modification

technique that will inhibit the surface induced thrombosis and enhance the long-term
blood compatibility of Quatromer. Six different phospholipids were grafted in the

Quatromer and the role of each of the modified substrates was evaluated in terms of
mechanical properties and hemocompatibility. The surface analysis studies showed a
significant decrease in contact angle while an increase in the surface energy and the O/C
ratio with phospholipid modification, indicating a highly hydrophilic surface with
increased carbonyl groups on the surface contributing to lower platelet adhesion and
activation. The comparative platelet adhesion tests showed significant decrease in platelet
adhesion with phospholipid modification. Hence, phospholipid modification proves to be
promising in increasing the long-term blood compatibility of Quatromer.
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CHAPTER

I

INTRODUCTION
1.0

Introduction
"The heart, consequently, is the beginning of life; the sun of the microcosm, even

as the sun in his turn might well be designated the heart of the world,for it is the heart by
whose virtue and pulse the blood is moved, perfected, and made nutrient, and is
preservedfrom corruption and coagulation"- William Harvey (1578-1657)

Heart valve diseases remain a major public health issue. Since their introduction
in 1960's, prosthetic heart valves have significantly improved the quality of life for
millions of patients worldwide (Edmunds 2001).

According to American Heart

Association's (AHA) 2003 Heart and Stroke Statistical Update, in 2001 an approximate
82,000 valve replacement procedures were performed in the United States. It has been
estimated by the American Heart Association's 2003 Heart and Stroke Statistical Update,
that the valvular heart disease is responsible for nearly 19,737 deaths each year in the
United States and is a contributing factor in about 42,100 deaths. This indicates a need to
introduce improvements in the valve material and design to minimize thrombotic
potential and material degradation and to improve morbidity and mortality outcomes
(Schoephoerster and Chandran 1991). This study is directed towards the improvements
in valve material, which can lead to minimization of thrombotic potential that can
eventually help in the development of novel artificial heart valve material.

I

Heart valve prostheses are basically divided into three groups: 1)

mechanical

valves, which are fabricated from metal or pyrolytic carbon that directs the flow of blood
through tilting or caged discs or with closure of a ball in a cage; 2) bioprosthetic valves,
which are tri-leaflet treated aortic valves fabricated from pig (porcine) or pericardium of
cows (bovine); and 3) polymer trileaflet valves, which are fabricated from flexible inert
synthetic materials. Mechanical valves are structurally designed to last a lifetime, but
require potent blood thinners to decrease the tendency to form blood clots (Gray RJ
1996). According to the American Heart Association's 2003 Heart and Stroke Statistical
Update, thromboembolic complications occur with 13-17% of mechanical valves within
5 years of implantation and with 34-44% within 15 years of implantation. Bioprosthetic
valves demonstrate advantages in native blood flow characteristics of natural valves,
however, have limited durability due to stiffening of calcified leaflets (Schoen 1983;
Ozaki 2003). Polymer tri-leaflet valves are constructed from biochemically inert
synthetic materials having excellent blood flow characteristics as well as having the
prospective to last for a long time (Imamura and Kaye 1977). However, they have not
yet been successful due to long-term structural degradation, resulting from oxidative
reactions with blood and high tensile and bending stresses originating in the material
(Beracca 1995). These synthetic materials are hydrophobic in nature and they tend to
accumulate platelets on the surface, which may later embolize. In particular, the
hemodynamic deterioration can result in complete obstruction of the polymer valve,
which can develop into a life-threatening condition. Patients with polymer heart valves
may have a high risk of thrombus formation on the valve and subsequent systemic
embolism (Little 5, 2003). These patients therefore need to receive life-long oral
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anticoagulation (QAC). The anti-coagulants cause birth defects in the first trimester of
fetal development, making the therapy unsuitable for pregnant women. Nevertheless,
complications related to thromboembolism and anticoagulant-related hemorrhage is to be
considered in deciding polymer heart valve prostheses (Tom 2004). According to the
American Heart Association's 2003 Heart and Stroke Statistical Update, anticoagulantrelated hemorrhagic complications of mechanical valves include major hemorrhage in 13%

of patients per year and minor hemorrhage in 4-8% of patients per year. The mortality

rate associated with surgical therapy for valve obstruction is approximately 15%.
The major purpose of this thesis was to investigate the possibilities of developing
a new modified polymer, which can be used to fabricate a non-thrombogenic and flexible
heart valve leaflet material.

The novel triblock polymer is composed of polystyrene-

polyisobutylene-polystyrene (Quatromer) copolymers, a proprietary polymer, modified
with six different kinds of commercially available phospholipids. It has been found that
Quatromer is less likely to degrade in vivo as compared to polyurethane (Pinchuk, Khan
et al. 1999). The modification with phospholipid may impart novel properties to

Quatromer. Phospholipids present in the outer membrane of human endothelial cell walls
have shown to impart great blood compatibility in vivo. The modification of Quatromer
may provide a superior biomaterial for trileaflet heart valves. In order to assess the
potential of the Quatromer/Phospholipid composite, various methods of modification as
well as the mechanical, surface and thrombogenic properties of Quatromer and various
types of phospholipid modified Quatromers were analyzed.

CHAPTER

11

BACKGROUND AND PREVIOUS WORK

2.0

Background
This first part of this chapter provides a general view on the cardiovascular

system and anatomy of the human heart. The initial part of the chapter also includes
details on the function of the heart, heart valves, the different types of valvular heart
diseases, their effects on the heart valve functioning and current treatment options for
valvular diseases. The second part of the chapter comprises the history and previous work
performed in the field of artificial heart valves. The third part of the chapter includes
polymer heart valves, its characterization, different polymers used in heart valves, blood
compatibility

of polymer heart

valves,

device hemocompatibility

factors, and

phospholipid mechanism in polymer modification.

2.1

Cardiovascular System
The cardiovascular system consists of the heart, circulatory system and cells and

plasma. The human circulatory system comprises of a network of vessels called arteries,
veins, and capillaries, which help transport blood to the various parts of the body and the
heart is a pump that pumps blood to the different parts of the body.

2.1.1

Heart
The heart is a strong muscular pump located between the lungs and to the left of

the sternum, and weighs between 7 and 15 ounces. The average heart beats 100,000
times, and pumps about 2,000 gallons of blood every day (Martini 2001). The heart wall

is comprised of a double-layered membrane called myocardium, and the layers of the
membrane are separated by a layer of fluid, which helps in providing lubricity. The heart
contains two upper (left and right atriums) and two lower (left and right ventricles),
which are separated by unidirectional valves.

cay
0

Figure 2.1

2.1.2

Anatomy

of human heart (Image courtesy of

htt)/wwsuM

evcm)

Heart Valves
The

human

heart has four valves, which control the blood flow in the heart. All

four heart valves are unidirectional or one-way valves, which allow the blood to flow

only in a single direction. The four types of heart valves are: 1) tricuspid (controls blood
flow between the right

from

atrium

and right ventricle), 2)

pulmonary

(controls blood

flow

the right ventricle to the pulmonary arteries), 3) mitral (controls blood flow between

the left atriu

and left ventricle), and ) aortic

to the aorta) (Figure 2.1).

(controls

blood

flow from the left ventricle

Each valve has a set of leaflets also known as flaps. The tricuspid, pulmonary, and

aortic valves have three leaflets while the mitral valve has two leaflets. It has been
observed that the failures of the heart valves on the left side of the heart are the most
common and deadly (Legrice 1997). Hence, the aortic and the mitral valves present on
the left side of the heart are subjected to the maximum damage due to higher-pressure
differences in the left ventricle of the heart. Thus, in order to develop an artificial heart
valve, the structure and function of a natural aortic valve would be studied and mimicked
as it represents a case of maximum stress loading in vivo.

2.1.3

Anatomy and function of natural aortic valve
The aortic heart valve primary function is to prevent the blood from flowing back

into the left ventricle from the aorta. The aortic valve performs 30-40 million cycles
every year, which results in approximately 3 billion cycles in a lifetime (Thubrikar 1990).
The above information shows that the fabrication of an artificial heart valves requires
careful understanding of the function and material structure of the human aortic heart
valve.

The aortic valve contains 90% water and other components such as collagen,
elastin, and glycosaminoglycans (GAGs) form an important part of the structure of the
valve (Cataloglu 1977; Sacks 1998). The collagen and elastin are the major components
responsible for providing the leaflet with its mechanical properties. One of the crucial
components for this research study is the glycosaminoglycans, which helps provide the
leaflets with required hemocompatibility (Baumann 1997). Studies performed have
shown that the hydrophilic glycosaminoglycans have been effective in decreasing protein
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deposition and fibrous tissue formation. One of the glycosaminoglycans, hyaluronic acid
(HA) has been used extensively in coating

medical

devices such as polyurethane heart

valves, stents, and intraocular lenses. Studies showed that hyaluron modification resulted
in good anticoagulant activity, low platelet aggregation, and favored the growth of human
endothelial cells (Baumann 1997).
The heart valve leaflets are comprised of three layers of tissue materials (Figure
2.2): 1) fibrosa, 2) spongiosa, and 3) ventricularis (Clark 1974: Sacks 1998). The fibrosa
is composed of collagen and is present on the aortic side of the valve. The ventricularis
layer is on the ventricle side and is composed of elastin. Spongiosa layer is present
between the fibrosa and ventricularis and consists of mainly glycosaminoglycans (GAGs)
and some collagen and elastin.

Figure 2.2 Three layers of aortic leaflet: fibrosa (F), spongiosa (S), and ventricularis (V)
(Clarke 1974)
2.1.4

Heart Valve Diseases
In recent years, heart valve diseases have become big threat to human life and one

of the primary treatments is surgery. According to the American Heart Association's
2003 Heart and Stroke Statistical Update, around five million Americans are diagnosed
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with valvular heart disease every year and is responsible for nearly 19,737 deaths every
year in the United States.
The malfunctioning of natural heart valves can result in several ways. The most

frequent causes of valve damage are rheumatic fever, birth or congenital defects, damage
from a heart attack, weakening of heart muscles and supporting structures in elderly, and
infections such as infective endocarditis (Rahimtoola 2000).

The diseases can cause

valve damage in two ways: stenosis and regurgitation. Valvular stenosis is characterized
by narrowing, stiffening, or blockage of valve thereby preventing free flow of blood.
Valvular regurgitation is a condition, which results in improper closing of the valve
thereby causing blood to flow in the wrong or back direction. The valves most commonly
affected are the aortic and mitral valves as they are subjected to higher-pressure
differences (Martini 2001). Thus, this study will focus on mimicking an aortic valve
structure and function for the development of a polymer heart valve.
In rheumatic fever disease, fusing of valve leaflets together or calcium deposition
on the tissues results in valvular stenosis. Rheumatic fever is responsible for 45% of
stenotic valve cases (Mark H. Beers,

17 th

edition).

Congenital or birth defects,

endocarditis infection, chronic hypertension causing aortic dilation, heart attack, and
autoimmune diseases are some of the causes responsible for valvular regurgitation
(Martini 2001). Some birth defects may not be serious enough for a surgery, yet their
presence may decrease life expectancy. Birth defects overall cause 20% of the valvular
regurgitation cases (Mark H. Beers,

1 7 th

edition).

Aortic dilation is another serious condition caused by the enlargement of the
sinuses of valsalva, where the leaflets are attached to each other (Butterfield 1993). The
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dilation is caused due to conditions such as hypertension or arteriosclerosis. Some
extreme cases of aortic dilation may require replacement of the entire valve.

2.2

Heart Valve Replacement
The first surgical replacement of a natural heart valve was performed successfully

in 1960s. According to the American Heart Association's 2003 Heart and Stroke
Statistical Update, it is estimated that around 82,000 valve replacements are performed in
the United States every year.

2.2.1

Types of Artificial Heart Valves
At present prosthetic heart valves are divided into three groups on the basis of the

material from which they are fabricated. The three types of artificial heart valves are
mechanical valves (fabricated from pyrolytic carbon or stainless steel alloys), prosthetic
tissue valves (fabricated from porcine or bovine pericardium), and synthetic or polymer
heart valves (fabricated from inert polymers such as polyurethane). Of the above three
classes of valves, only mechanical and tissue valves are commercially available and used
in valve replacement at present.

2.2.2

Mechanical Prosthetic Heart Valves
Mechanical heart valves are very durable, highly resistant to structural failure, and

can typically last more than 20 years without material degradation (Sapirstein and Smith
2001).

They are typically fabricated from biocompatible materials such as pyrolytic

carbon or metals alloys such as stainless steel alloys. However, the major drawback of
mechanical valves is that the surface tends to attract and activate platelets resulting in

surface thrombosis (Gray 1996). Thus, mechanical heart valves require patients to take
anticoagulation therapy indefinitely. However, patients with thrombogenic valvular
prostheses, carries a risk not only for valve thrombosis, but also a risk of bleeding
associated with anticoagulant therapy (Little 2003). Also, it has been demonstrated that
anticoagulation in extra-cardiac surgery, and anticoagulation in pregnancy, involving the
risk of embryopathy are some of the major complications associated with anticoagulation
therapy (Roudaut 2001). Currently, there are three general designs approved for
prosthetic mechanical heart valves: bileaflet, ball and cage, and tilting disc.
One of the earliest designs for mechanical valves was the ball and cage design
that uses a small ball entrapped within a metal cage. A typical example of the design is
the Starr-Edwards model. The Starr-Edwards model consists of a silicone ball enclosed
within a cobalt chromium alloy cage (Matthews 1998). As the blood flows through valve,
the flow presses the silicone ball against the aortic side of the cage thereby allowing
blood to flow around the ball (DeWall 2000). However, when there is back flow of the
blood, the ball is pressed against the ring thereby blocking the flow of the blood in the
reverse direction. One of the disadvantages of this heart valve was that the silicone rubber
would swell up by absorbing fluids in vivo and therefore would be stuck in the cage. Ball
and cage valves exhibit non-central flow characteristics, where the ball blocks the central
flow thereby causing the blood to flow around the ball (DeWall, 2000). This results in an
increase in stress on the heart, as the heart has to do additional work to compensate for
the energy lost due to the change in the direction of the blood. Also, as the ball blocks the
flow path of blood, a lot of blood cells are damaged and activated due to the collision
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with the ball. This damage of blood cells results in the activation of blood clotting agents,
thereby requiring lifelong anticoagulant therapy.

Figure 2.3 A Starr-Edwards Ball and Cage Heart Valve (Image courtesy of

http://people.hofstra.edu/facult /sina y rabban /engg8 1 /engg8l1courseoutline.html)
In the mid 1960s, a new design of mechanical valves was introduced, having a
circular tilting disc held in the middle by struts to prevent reverse flow. The Bjork-Shiley
model is one of the most famous valves based on this design (Edmunds 2001). The tilting
pattern helped in obtaining improved central blood flow characteristics than the ball and
cage model. The new model consisted of a tilting-disc fabricated using graphite or
pyrolytic carbon and is held together by struts prepared from stainless steel or titanium
(DeWall 2000). The disc between the two struts opens when the blood is passing through
it while closes when the blood tries to flow in the opposite direction. The tilting design
also helped reduce damage to blood cells by reducing their collision with the metal
surface due to the central flow characteristics. Yet, one of the major problems with this
design is the failure of the struts resulting from the fatigue caused by repeated movement
of the struts (DeWall 2000).
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Figure 2.4 Medtronic-Hall Tilted Disk Valve (Image courtesy of
http://people.hofstra.edu/faculty/sina y rabbany/engg8 1 /engg8 1 courseoutline.html)
In 1979, St. Jude Medical introduced a new kind of mechanical heart valve design
known as the bileaflet valve design and today it is the most used design for the
manufacture of mechanical heart valves (DeWall 2000). The bileaflet model has two
semicircular discs that are held by hinges and have a movement similar to a door. The
two discs are fabricated from pyrolytic carbon, having high strength. The greatest
advantage of this design was the presence of a larger orifice area compared to the other
designs thereby providing the best central flow characteristics (Montorsi 1996). Yet, the
major drawback was that the leaflets did not close completely, which caused some
leakage of blood in the reverse direction.

Figure 2.5 St. Jude Medical Mechanical Bileaflet Heart Valve (Image courtesy of
1 courseoutline.html)
I /n
raban /en
http//people.hofstra.ed/facult /sina
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2.2.3

Bioprosthetic Heart Valves
Bioprosthetic tissue valves can be basically divided into two categories, namely

human tissue valves and animal tissue valves. The tissue valves have many advantages
over the mechanical valves as they have better hemodynamics, prevent damage to the
blood cells (central flow characteristics) and hence, eliminate the need for a permanent
anti-coagulation therapy. However, they suffer from long-term material degradation due
to the calcification of the tissue.
Human

tissue valves can be classified as:

Homografts

and Autografts.

Homografts also known as Allografts are human valves that are transplanted from a dead
donor to a patient (Sapirstein and Smith 2001; Chew et al., 1994). The homografts have
various other advantages compared to tissue valves as they provide high resistance to
infective endocarditis, native hemodynamic flow characteristics, good durability, and no
immunosuppressive treatment, as the organ rejection is minimal (Sapirstein and Smith
2001). However, one of the major drawbacks is the limited availability of donors. The
Autografts are human tissue valves that are obtained from the same patient they are to be
implanted into. An autograft surgery involves substituting patient's defective aortic valve
with the patients own pulmonic valve, and the pulmonic valve with a new artificial valve

(Sapirstein and Smith 2001).
Animal tissue valves are also divided into two groups: porcine (pig) valves and
bovine (cow) valves (Chew et al., 1994). The tissue components of the heart valve are
obtained from either the pericardial tissue of a pig or a cow. The tissue components are
kept in glutaraldehyde to increase biocompatibility and to crosslink the collagen fibers
thereby improving the strength of the tissue. However, the crosslinking of collagen fibers
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has been responsible in causing calcification. The deposition of calcium causes the
stiffening of the leaflets, which ultimately leads to the tearing of the leaflets, and may
also cause blockage of blood flow (Schoen 1983; Ozaki 2003). Hence, the animal tissue
valves are required to be replaced

more

frequently than mechanical heart valves. The

animal tissue valves can be fabricated either with a frame or without a frame (stentless).
The stented tissue valves have the valve sewn to a metal or a plastic frame and the frame
is then covered with cloth or Dacron. The stentless valves use the patient's own aortic
wall for support (Luciani 2004).

Figure 2.6 A LifeNet Allograft and a Toronto SPV@ Tissue Valve (Image courtesy of

http://heartvalvebank.info/HVB
2.2.4

valves.php)

Polymeric Tri-leaflet Heart Valves
Polymer heart valves are a new class of heart valves, which have the potential to

eliminate the drawbacks present in mechanical and tissue heart valves. The polymeric
heart valves are fabricated from biochemically inert synthetic materials, which are
designed to have long-term structural and functional stability inside the body (Hyde et al.,
1999). The flexible trileaflet structure of the valve enables to provide the combination of
superior hemocompatibility (native flow characteristics) and long-term biological and
mechanical properties (resistant to oxidation in vivo). They have a potential to eliminate
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the anticoagulation therapy required in mechanical valves and provide resistance to
material degradation encountered in tissue valves.

Various kinds of polymeric heart valves have been developed and tested both in
vitro and in vivo. However, each of them has encountered structural degradation in vivo,
which has prevented their commercial success. The next section outlines material
degradation faced by different polymers used in fabrication of artificial heart valves in
vivo. New significant developments in the field of surface modification of the polymers
may help prevent potential problems such as thrombus and calcification, and the early in
vitro and in vivo results have been quite promising (Bemacca and Wheatley 1998). One
of the most commonly used polymers in polymeric heart valves is polyurethane
(Bemacca, Mackay et al. 1995; Bemacca, O'Connor et al. 2002). Polyurethanes have
performed well in terms of tensile strength, but have been observed to fail due to
oxidation reactions with blood at high bending stresses.

Figure 2.7 Synthetic (Quatromer) Heart Valve (Image courtesy of wwinva-lM
2.3

o)

Different Polymers in Synthetic Heart Valves
One of the earliest polymers used in polymer heart valves was siliconee rubber,

but the material failed under prolong and high fatigue and bending stresses (Chetta and
Lloyd 1980; Parfeev, Grushetskii et al. 1982).
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Another polymer used in the early

developments was Polytetrafluoroethylene, however, the material failed in vivo due to
thrombosis and more prominently due to calcium deposits in the commissural region
(Nistal et al. 1990).
PGA-PLA (polyglycolic acid/polylactid acid) copolymer was another biomaterial
used in fabrication of prosthetic valve leaflets, however this polymer was unsuitable as it
was too immalleable to form flexible leaflets (Stock and Mayer 2001). Studies were also
carried out to use PLA-PVA (poly (lactic acid)-g-poly (vinyl alcohol)) polymers in
prosthetic heart valve, however the polymer is not yet successful in long term durability
studies (Nuttelman et al. 2002). A study carried out by Sodian and his colleagues showed
the use of polyhydroxyalkanoates (PHAs), particularly polyhydroxyoctanoate (PHO) in
the fabrication of tissue leaflets (Sodian et al. 2000).

Polyhydroxyoctanoate (PHO) is

biodegradable, biocompatible polyester that proved to be better than the PLA-PGA and
PLA-PVA polymers in terms of flexibility, biocompatibility, and mechanical properties;
however it also suffered from material degradation over prolonged period in vivo. To
overcome the problems faced by PHO, recently Hoerstrup and colleagues developed a
new composite material having PGA coated with poly-4-hydroxybutyrate (P4HB), which
has a higher degradation time than PHO (Dvorin et al. 2003).
Most recently, Victrex (Lancashire, United Kingdom) has developed PEEK
(polyaryletheretherketone) polymer, which is been used by Aortech international to
fabricate heart valves. The PEEK valves are currently under clinical studies.
One of the most often used polymers for synthetic heart valves has been
polyurethane. Over the past twenty years various forms of polyurethanes have been used
in the making of synthetic heart valves (Chetta and Lloyd 1980; Bemacca, Mackay et al.
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1995; Bemacca, O'Connor et al. 2002). Polyurethane materials are thermoplastic
elastomers having high tensile strength and relatively good biocompatibility, yet they
suffer structural degradation due to calcification.

2.4

Mechanism of Blood Coagulation and Device Hemocompatibility
Blood compatibility is one of the most required and desired properties in the

development of medical devices. The response of blood in contact with foreign materials
can be aggressive, resulting in a highly unfavorable condition such as surface induced
thrombosis or blood clots. One of the major risks associated with thrombosis is the
detachment of thrombi embolism from the surface of the device and flowing downstream
and blocking the smaller vessels thereby blocking the vessels, which may result in severe
complications such as stroke or even death. According to AHA's 2003 Heart and Stroke
Statistical

Update,

approximately 4-2%

thrombosis

and

thromboembolism

complications

results

in

of prosthetic heart valve patients. Hence, it becomes vital to

evaluate and diagnose the thrombotic potential of a biomaterial before it is introduced in
the device fabrication phase.

2.4.1

Blood Coagulation
Blood is composed of various types of cells, platelets, and proteins known as

blood coagulation factors, which are numbered from I-XIII (Guyton and Hall 1996).
When the body suffers an injury, it initiates a process called homeostasis to stop bleeding
by the mechanism of blood coagulation. However, when this blood comes in contact with
external materials, the coagulation factors are activated and an enzyme called Thrombin
is secreted. Thrombin is then responsible in converting the protein fibrinogen into an
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insoluble product known as fibrin. This fibrin is the main component, which helps in the
aggregation of blood cells and platelets (Colman

1994; Grunkemeier 2000). The

aggregates of activated platelets tend to join each other on the surface thereby forming
fibrin clots. Hence, when a medical device comes in contact with blood, one of the
inactive proteins called factor XII is adsorbed on the foreign surface. Upon deposition on
the foreign surface, the factor XII becomes active to factor XIIa and it begins the cycle of
coagulation (Blockmans 1995; Grunkemeier 2000). The activated factor XIIa is needed
for the cross linking of fibrin molecules. As more and more fibrinogen is converted to
fibrin, a network of fibrin is created in the presence of factor XIa, which entraps platelets
on the surface of the material. The platelets on attaching to the surface become activated,
thereby releasing chemicals, which attract other platelets in the vicinity, inducing the
formation of platelet aggregates. The aggregated platelets on the surface produce more
thrombin inducing further fibrinogen to fibrin conversion, thereby aggravating the
coagulation process (Colman 1994; Blockmans 1995; Grunkemeier 2000).
Th co gulation cacde

.

8
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Figure 2.8 Platelet coagulation cycle and Platelet activation (Colman 1994)
2.4.2

Device Hemocompatibility
Every device has the potential to form thrombosis on the surface by the presence

of various clinical and design factors. The various factors responsible

for the

hemocompatibility of medical devices are blood flow dynamics, device geometry, surface
roughness, medical device material, duration of blood contact, and surface area (Vroman

1988; Hirsh 1983; Ratner 1996).
2.4.2.1 Blood Flow Dynamics
The blood flow controls such as blood shear rates, and turbulence are important
factors affecting the amount as well as the composition of blood proteins transported to
the device surface. The level of shear stress plays an important role in the adhesion as
well as the activation of the platelets. At low flow rates, a red thrombus is formed, which
contains a large amount of fibrin binding platelets and red blood cells. The formation of
red thrombus results at low flow rates as there is enough time for the proteins to bind to
fibrinogen in order to completely bind the platelets (Harker 1974). When the medical
device is kept in a high flow, a white thrombus is formed and it contains a large amount
of platelets bonded by smaller amounts of fibrin (Harker 1974). The formation of white
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thrombus results at higher flow rates as there is limited time for the coagulation cycle to
form fibrin while the platelet cycle takes place, as it only requires an adhesion site for the
activation of the platelets (Harker 1974; Slack 1993). In cases of flow disturbances or
turbulence in blood flow (arterial stenosis, and vessel bifurcations), slow shear
recirculation regions would form, which would result in the formation of a large amount
of fibrin (Harker 1974). Thus, turbulence would result in an increase in the activation and
transportation of platelets and coagulation factors.

2.4.2.2 Device Geometry
The geometry of the device can be a major contributing factor to determine the
blood flow characteristics. The surface (sharp curves and bifurcations) of medical devices
may result in turbulence in the blood flow thereby causing aggravated platelet adhesion
and activation at the surface (Vroman 1988; Ratner 1996).

2.4.2.3 Surface Roughness
The degree of surface roughness plays a vital role in contributing towards the
device hemocompatibility (Brash 1987; Horbett 1993; Andrade 1996). It is observed that
rough surfaces tend to have an attacking nature and hence, they tend to accumulate more
platelets on the surface. The irregular rough surface results in the formation of microturbulence areas, thereby making it more susceptible to attract and activate platelets on
the surface. Platelet studies performed on polished surfaces having smoother surfaces
tend to show lower thrombogenic potential than unpolished ones (Andrade 1996).
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2.4.2.4 Medical Device Material
The surface chemistry of the device material is very important in providing the
device with its blood compatibility. Various surface properties such as degree of
hydrophilicity, surface energy, surface charges (anionic or cationic), and crystallinity
contribute to the hemocompatibility of a medical device (Vroman 1988; Hirsh 1983;
Ratner 1996). For the device material to be highly hemocompatible, ideally it should be
highly hydrophilic, non-ionic, inhomogeneous, non-crystalline, and have high surface
energy.

2.4.2.5 Duration of Blood Contact
The time for each a device is in contact with blood can help determine the
reaction of the blood with the device material (Hirsh 1983). Time has a direct relation
with platelet deposition i.e. the more the material contact time with blood, the greater the
amount of platelets deposited on the surface. Heart valves, which are typically implanted
for years, may result in systemic effects such as infection, anemia or calcification over
time due to the presence of proteins layers on the device surface (Vroman 1988).

2.4.2.6 Surface Area
Surface area is also directly proportional to amount of platelets deposited on the
surface. The greater the material contact surface exposed to platelets, the more platelets
attached to the surface. Medical devices having large surfaces can result in conditions
such as anemia as a lot of red blood cells are attached on the surface thereby reducing the
amount of red cells flowing in the blood (Vroman 1988).
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2.5

Hemocompatibility of Polymers in Vivo
Polyurethane materials have been the typical choice for biomedical implants due

to their high tensile strength, and good hydrodynamic flow characteristics (Bemacca
2002). The polyurethane materials have also been shown to survive 400 million cycles in
fatigue testing (Jansen and Reul 1992), yet they have not been proved to be
hemocompatible under in vivo conditions, which has limited its use in medical
applications. Various mechanical testing studies performed on polyurethanes (PUs) show
that the mechanical properties (fatigue resistance, toughness, flexibility, and durability)
of polyurethanes meet requirements for clinical applications, yet when the polyurethanes
come in contact with blood, activation of platelets on the polyurethane surface occurs,
which

decreases

its

long-term

hemocompatibility

(Morimoto

et

al.

2002).

Hemocompatiblity studies carried on polyurethanes showed that the hemocompatibility
of the polymer correlated closely with hard segment content and chemical composition of
the polymer (Groth and Klosz 1994). Platelet deposition studies showed that the adhesion
and activation of plasma proteins, lymphocytes, and platelets increased with increasing
hard segment content of the polyurethane (Chen and Wei 1998; Mitzner and Groth 1996).
When the blood compatibilities of soft segments of polyurethanes (poly (butadiene), poly
(isoprene)) and hard segments of polyurethanes (1,4-butanediol) were evaluated using
platelet-rich plasma, it was found that the soft segments of polyurethanes (poly
(isoprene)) exhibited lower platelet adhesion (Li et al, 1996). The various platelet
deposition studies preformed on polyurethanes have showed that they have a high
potential to adhere platelets on their surface.
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For the fabrication of the novel trileaflet heart valve, a proprietary polymer, called

Quatromer (Innovia LLC, Miami, FL), which is a polystyrene-polyisobutylenepolystyrene triblock copolymer is selected. Basically, the polymer is composed of a
gummy material i.e. polyisobutylene restricted between two hard blocks i.e. polystyrene.
It has been found that the Quatromer is highly resistant to oxidation in vivo due to the
absence of ester and ether bonds as well as the backbone of the polymer has sites that
can support double bond formation (Pinchuk et al, 1988). However, platelet adhesion
studies carried out on polystyrene surface have shown that the polystyrene surfaces have
high reactivity for platelet adhesion (Carretero et al. 1994). The platelet studies
performed on polystyrene have shown that the hydrophobic nature of polystyrene is one
of the vital factors in attracting platelets on the surface. Recently, platelet deposition
studies performed on Quatromer and polyurethane have shown that they have equal
platelet deposition on their surfaces. This shows that the Quatromer has a high potential
to attract platelets on its surface as studies performed on polyurethane have shown high
number of platelets adhering to the surface.
Thus, modification of the Quatromer is required to enhance its resistance to
thrombosis. One of the methods to reduce the thrombotic potential of the Quatromer is to
modify it with phospholipid. The phospholipids tend to bind water loosely around them
thereby increase the amount of water molecules on the polymer surface, and thus,
decreasing the platelet adsorption on the surface.

23

2.6

Preliminary work performed in modification of Quatromer
One of the most vital objectives of this thesis is to increase the hydrophilicity of

the Quatromer. Quatromer is basically composed of polystyrene and polyisobutylene
copolymers and both the materials have been shown to be significantly hydrophobic in
nature. Experiments carried out by Carretero have shown that hydrophobic polystyrene
surfaces tend to have high potential for platelet adhesion. Also, the surface analysis of
Quatromer surface performed using sessile water drop method has shown that the
Quatromer surface has a high contact angle indicating high hydrophobicity of the
Quatromer material. In order to increase Quatromer's surface hydrophilicity, a range of
surfactants was selected. The contact angle and surface energy of each of the surfactant
modified Quatromers were determined to assess the potential of the surfactant in
lowering the contact angle of Quatromer. Various, surfactants namely sotradecol (sodium
tetra decyl sulfate), n-butyl methacrylate, Alginic acid, Acrylic acid, Phytic acid, Poly(Llactide),

Hyaluronic

Phosphatidylcholine,

acid,

Didodecyldimethylammonium

Phosphatidylethanolamine,

bromide,

Heparin,

1,2-Dimyristoyl-rac-glycero-3-

phosphocholine, and 1,2-Didodecanoyl-rac-glycero-3-phosphocholine were used initially
to modify the Quatromer and the surface analysis was carried out for each of them. The
contact angle measurements showed that the phospholipids tend to show the smallest
contact angles indicating their potential in increasing the hydrophilicity of the Quatromer.
The contact angle measurements helped us to narrow the range of surfactants used to
modify the Quatromer to just phospholipids. After deciding that phospholipids would be
the best choice for modifying Quatromer,

two new phospholipids 1,2-Dioleoyl-sn-

Glycero-3-Phosphocholine, and 1,2-Diarachidonoyl-sn-Glycero-3-Phoshocholine were
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added to evaluate the effect of degree of phospholipid unsaturation and phospholipid
chain length on hydrophilicity and platelet deposition on Quatromer surface. Thus, in
total six different saturated and unsaturated phospholipids were selected to modify the

Quatromer and to evaluate the role of each in enhancing the long-term hemocompatibility
of the Quatromer.

2.7

Previous work performed in phosholipid modification of polymers
Phospholipids are found predominantly in the outer membrane layer of the cell.

They are zwitterionic molecules, which carry both positive and negative charges with a
net charge of zero. They zwiiterionic nature helps increase the free water on the surface
thereby reducing surface thrombosis. This unique property of phospholipids has helped
them achieve recognition as the typical material of choice for modifying polymers to
increase their blood compatibility (Hayward and Chapman 1984). Since the last 20 years,
many studies have been carried out on modifying different polymers using different types

of phospholipids.
To achieve

novel hemocompatible

polymer surfaces,

polyurethanes were

modified with 2-methacryloyloxyethyl phosphorylcholine (MPC) to form a polymer
network. Platelet adhesion studies showed that unmodified polyurethanes had a high level
of platelet attachment before and after stress loading while MPC modified polyurethanes
prevented platelet adhesion even after stress loading (Ishihara et al. 2000; Morimoto et al.
2002). On analyzing the polymer composite, it was found that the MPC unit was
concentrated at the surface of the polyurethane membrane, which organized itself into a
self-assembled membrane and thus contacted with the plasma proteins (Ishihara et al.
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2000).

Studies

on poly

(ether

urethane)

(PEU)

modification

using

dioleoyl

phosphatidylcholine (DOPC) demonstrated that the blood compatibility of PEU was
improved

by embedding

phospholipid

groups

on the

surface.

The

improved

hemocompatibility was indicated by a decrease in platelet activation and adsorption on
the PEU surface (van der Heiden AP 1998). The data from the study showed that the
contact angle of the phospholipid modified polymer decreased thereby increasing the
hydrophilicity of the surface. One of the main points that the study highlighted was the
fact that the presence of mere phospholipid groups was not sufficient in reducing the
platelet adhesion, rather the formation of "biomembrane-like" DOPC bilayer was
responsible for the reduction in platelet adhesion (van der Heiden AP 1998).
Platelet studies performed on methacryloyloxyalkyl phosphorylcholine (MAPC)
polymer showed that the addition of dimyrstoyl phosphatidylcholine (DMPC) further
reduced the amount of fibrinogen absorbed on the MAPC surface (Iwasaki Y et al. 1999).
The modification of L-lactide polymer using L-alpha-glycelophosphorylcholine (LGPC)
resulted in the formation of a biodegradable polymer having good hemocompatibility and
antiadhesive properties (Iwasaki Y et al. 2003). The studies mentioned above shows that
phospholipids have a great potential in rendering polymeric materials with high
hemocompatibility. To achieve the biomembrane properties, the biomedical Quatromer
will be modified using different phospholipids to promote the creation of functional
groups, such as phosphate, and carbonyl groups. The modifications are expected to
enhance Quatromer's long-term implant hemocompatibility as well as impart other
material properties such as reduced surface friction and tackiness.
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2.8

Proposed Phosphatidylcholine (PC) Mechanism
Phosphatidylcholine (PC) belongs to the group of phospholipids and it is basically

a fat derivative where the head group has one of the fatty acids replaced by a phosphate
group. Phosphatidylcholine molecule is amphiphilic i.e. it has a hydrophobic tail (fatty
acid end not attracted to water) and a hydrophilic head group (phosphate group attracted
to water). Phospholipids have a unique property to self-assemble to form bilayers (Figure
2.10) in aqueous environment where the hydrophilic phosphate head group orients
towards the outside while the hydrophobic tail points inwards (Campbell 1994). These
bilayers having hydrophilic head groups are the predominant factors responsible for the
hemocompatibility of biomaterials (van der Heiden et al 1998).

Figure 2.9 Phosphatidylcholine self-assembling bilayers and head group water-binding
mechanism (Image courtesy of www.biocompatibles.co.uk/)
One of the proposed mechanisms, which help Phosphatidylcholine in reducing
platelet adhesion on polymer substrate,

is presented

in this paragraph.

When

phosphatidylcholine comes in contact with water, it possibly assumes a hydration state
where the hydrophilic head groups bind free water around it through vanderwaal forces
(Ishihara 1998) (Figure 2.10). It is believed that when a protein comes in contact with the
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surface of the polymer, the protein tends to loose its solvation water thereby attaching the

hydrophobic part of the protein to the polymer surface. However, when the polymer is
modified with phosphatidylcholine, the phosphate head group is supposed to tightly bind
free water molecules around it. The presence of these free water molecules around the
head groups is believed to cause the state of water molecules on the polymer surface to be
the same as the one present around the proteins and this possibly prevents the proteins
from releasing their solvation water molecule (Yianni 1992). Therefore, the failure of the
protein to release their solvation water molecule is one the possible vital factors, which
prevents the hydrophobic interactions between the protein and the polymer surface
(Figure 2.11). Hence, phosphatidylcholine modified polymers possibly induces presence
of free water molecules on the polymer surface thereby restricting the protein
hydrophobic interactions and thus improving the hemocompatibility of the modified
polymer (Dudley et al. 1993).

Figure 2.10 Proposed PC mechanism in preventing protein biomaterial interaction
(Image courtesy of ww).biocompatibles.coukl)
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2.9

Types of Phospholipids used in this research study

a.

Phosphatidylcholine (Lecithin)

o

It H

Figure 2.11 Phosphatidylcholine Structure
Phosphatidylcholine

(PC)

also

known

as

1,2-Diacyl-sn-Glycero-3-

Phosphocholine is one of the most known member of the fat-soluble substances known as
phospholipids. PC is an unsaturated phospholipid with a numerical formula of 18:

1

9

which denotes a hydrocarbon chain with 18 carbon atoms and one cis double bond
between the ninth and tenth carbon atom. PC is the most abundant phospholipid found in
animals and plants. Phosphatidylcholine is the major component in the formation of the
outer layer of the plasma membrane of the cells. It is a zwitterionic (neutral) molecule i.e.
it has positive and negative charged groups with a net charge of zero. Lecithin is believed
to help in fighting arteriosclerosis, digestion of fats, immune disorders, and liver
disorders.
b.

Phosphatidylethanolamine (Cephalin)

HH
H

Figure 2.12 Phosphatidylethanolamine Structure
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Phosphatidylethanolamine (PE) is nitrogenous unsaturated fatty acids and they are
the second most abundant phospholipids found in living organisms. PE is an unsaturated
phospholipid denoted numerically as 18:29,12 having 18 carbon atoms and two cis double
bonds at the ninth and twelfth carbon atoms. PE also forms one of the major building
blocks of the cell membrane, especially microbial membranes. Phosphatidyicholine is
also a zwitterionic or neutral molecule having polar and non-polar groups. They play an
important role in the assembling of membrane proteins and also help in the growth of
endothelial cells.
c.

1,2-Dioleoyl-sn-Glycero-3-Phosphocholine (DOPC)

iH

Figure 2.13 DOPC Structure
This phospholipid has an 18-carbon unsaturated fatty acid having one cis double
bond (oleic acid) at the ninth carbon atom in each hydrocarbon chain and is denoted as
18:1 "". The double bond is responsible in producing a twist or a kink in the hydrocarbon
chain.
d.

1,2-Diarachidonoyl-sn-Glycero-3-Phoshocholine (DAPC)

Figure 2.14 DAPC Structure
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This is a 20-carbon unsaturated fatty acid having four cis double bonds
91 5

(arachidonic acid) and is designated as 20:4",2

15

, 18. It is one of the phospholipids,

which forms a major constituent in prostagladins. This phospholipid is highly susceptible
to oxidation due to the presence of a high degree of unsaturation in the hydrocarbon
chain. The double bonds are susceptible to cleavage in vivo forming free radicals or
peroxides which are highly unstable in nature.
1,2-Dimyristoyl-sn-Glycero-3-Phosphocholine (DMPC)

e.

N

Figure 2.15 DMPC Structure
This is one of the most basic and saturated phospholipid having 14 carbon atoms
and no double bonds in the hydrocarbon tail. The phospholipid is denoted as 14:0
numerically, and has a highly ordered and stable structure. The absence of the double
bond helps this phospholipid in forming a more compact bilayer arrangement. This
phospholipid has been widely used in the modification of different polymers.
f.

1,2-Didodecanoyl-sn-Glycero-3-Phosphocholine (DDPC)

0

O0

Figure 2.16 DDPC Structure
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1,2-didodecanoyl-sn-Glycero-3-Phosphocholine

(DDPC) also known, as 1,2-

Dilauroyl-sn-Glycero-3-Phosphocholine (DLPC) is a 12-carbon atom saturated fatty acid
without any double bonds in the structure and is denoted as 12:0. This phospholipid has a
highly ordered structure and is highly hydrophilic in nature.

2.10

Statement and Significance of Problem
Blood compatibility has been the major concern in the development of artificial

heart valves since foreign surfaces induce thrombosis upon contact with blood. Heart
valve prostheses have been used successfully for half a century in improvement in the
longevity of patients with valvular diseases (Edmunds 2001). According to the American
Heart Association AHA's 2003 Heart and Stroke Statistical Update, heart valve
mortalities in 2001 were around 19,737, which are still pretty high. Thrombosis and
thromboembolism have been major sources of mortalities in cardiovascular devices and
hence, efforts are required to introduce improvements in artificial valve material and
design to minimize thrombotic potential and material degradation and to improve the
morbidity and mortality outcomes (Schoephoerster and Chandran 1991). It is therefore
necessary to diagnose and evaluate the blood compatibility of foreign materials before
they are considered in the development of artificial organs. Modified synthetic polymer
heart valves have shown potential to reduce the thrombogenicity and structural
degradation associated with the prosthetic heart valves. Quatromer polymer trileaflet
valve offers natural valve hemodynamics with the potential for sufficient durability for
long-term use. However, hemocompatibility of synthetic polymers has been one of the
limiting factors in the development of polymeric medical devices and artificial organs
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due the interaction of blood upon contact with hydrophobic polymer surface, resulting in
surface thrombosis.
Patients with polymer heart valves may have a high risk of thrombus formation on
the valve and subsequent systemic embolism. These patients therefore need to receive
life-long

oral

anticoagulation

(OAC).

Nevertheless,

complications

related

to

thromboembolism and anticoagulant-related hemorrhage is to be considered in deciding
polymer heart valve prostheses. Modem oral anticoagulant therapy is found to be far
from ideal. Every patient, with thrombogenic valvular prostheses, carries a risk not just
for valve thrombosis, but also a risk of bleeding which follows anticoagulant therapy
(Little S, 2003). Also, it has been found that anticoagulation in extra-cardiac surgery and
anticoagulation in pregnancy are some of the major complications associated with
anticoagulation therapy (Roudaut R, 2001). These complications associated with valvular
prostheses and anticoagulation therapy requires efforts to develop a new modified
material and technique to reduce or possibly eliminate the complications associated with
artificial heart valves.
As a result of the numerous complications associated with valvular prostheses,
decreased incidence of thromboembolic complications can be achieved by improved
thromboresistance of the new valve material rather than anticoagulant therapy. A
polystyrene-polyisobutylene-polystyrene (Quatromer)

triblock

copolymer,

a novel

proprietary polymer is being used in the development of the synthetic heart valve. It has
been found that Quatromer is found to be less likely to degrade in oxidative and acidic
environments than Polyurethane (Pinchuk, Khan et al. 1999), which are the typical
conditions likely to be encountered in vivo. However, it is unclear whether Quatromer
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valves will suffer from some of the complications associated with the standard valves
such as surface thrombosis.
In order to evaluate the thrombotic potential of Quatromer and the feasibility of a
modified novel Quatromer as heart valve material, the surface characterization,
mechanical properties, and platelet adhesion studies for Quatromer would be compared
with six different phospholipid modified Quatromers. Extensive research work has been
carried out on phospholipid modification of polymers, yet there are no comparative
studies performed, which highlight the effects of different saturated and unsaturated
phospholipids having varying hydrocarbon chain length on the same polymer. This
research

study

phosphocholine
(DDPC)),

involves
(DMPC),

saturated
and

phospholipids

(1,2-Dimyristoyl-rac-glycero-3-

1,2-Didodecanoyl-rac-glycero-3-phosphocholine

unsaturated phospholipids (Phosphatidylcholine (PC),

Glycero-3-Phosphocholine
Phosphocholine (DAPC)),

and

(DOPC),

1,2-Dilinoleoyl-sn-

1,2-Diarachidonoyl-sn-Glycero-3-

and nitrogenous phospholipid (Phosphatidylethanolamine

(EPC)). Basically, the Quatromer is modified with the saturated, unsaturated, and
nitrogenated phospholipids and the effect of phospholipid acyl chain unsaturation, chain
length, and presence of amine groups on hemocompatibility, material strength, and
oxidation resistance of the Quatromer is determined. The study compares the effect of
each of the different phospholipids on a single polymer i.e. Quatromer and this
distinguishes this research from other phospholipid modification studies. Moreover,
Quatromer is a newly invented elastomer, and this would be a first of a kind modification
study for the Quatromer thereby evaluating and comparing the hemocompatibility of the

Quatromer

as well as different surfactant modified Quatromers. Most of the research
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studies carried out on the modification of polymers performed either the 1) surface
characterization tests or 2) platelet adhesion tests or 3) mechanical tests for the newly
modified polymers, however, this study compares all the three above mentioned aspects
of polymer evaluation. Research studies have been performed using some of the above
mentioned phospholipids such as 1,2-Dilinoleoyl-sn-Glycero-3-Phosphocholine (van der
Heiden AP 1998), however the studies were performed on other polymers such as poly
(ether urethane) (PEU) and the study also did not compare different phospholipids on the
same polymer as well as the did not involve mechanical testing of the modified
substrates. Hence, the above mentioned aspects would help in distinguishing this study
from others as well as in evaluating the thrombotic potential of Quatromer and modified

Quatromer in the fabrication of a novel trileaflet heart valve.
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CHAPTER

III

METHODOLOGY
3.0

Methodology
The materials and methodology used in this study are divided into three groups,

each of which represents the different phase of testing. The first phase of testing is the
mechanical testing of the specimens. The second phase is comprised of the surface
characterization of polymers. The last phase is the comparative thrombogenic test or
platelet adhesion test of the polymers.

3.1

Sulfonation of Quatromer
A proprietary process (Innovia LLC) of sulfonating the Quatromer (lot#09200)

was employed to determine its potential in enhancing the hemocompatibility of the
Quatromer surface. The sulfonation technique was used to create negatively charged
SO 3H groups on the surface. The sulfonation process for Quatromer is not disclosed due
to the proprietary nature. However, in order to confirm the generation of sulfonate groups
on the Quatromer surface, methylene blue staining test was performed. On staining the
surface with methylene blue dye, if the surface turns blue in color then it shows the
presence of SO 3H (sulfonate groups) on the Quatromer surface while the lack of staining
would prove the absence of sulfonate groups on the surface (Pizzolato 1975). Basically,
methylene blue is a cationic sulfonate sensitive dye and when used to stain a sulfonated
polymer, the anionic sulfonated polymer forms ion pairs with the cationic methylene blue
dye. Thus, the sulfonated polymer forms a blue colored complex with the methylene dye
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and this helps in staining the surface of a sulfonated polymer blue while an unsulfonated
polymer does not form blue colored complex with methylene blue dye (Pizzolato 1975).

3.2

Phospholipid/Quatromer modification
The phospholipid modified Quatromer was prepared by surface dip coating

process as well as using a simple phase mixing process.
The surface modification of Quatromer is carried out using a simple dipping
process. Dip coating of polymers is a simple process, which basically binds the surfactant
to the desired substrate. The method is quick, easy, and is relatively inexpensive.
Rectangular samples of Quatromer were prepared using a plate assembly (Appendix A)
and the samples were then dipped in a 20% (w/w) phospholipid/Quatromer composite. A
20%

(w/w) solution of phospholipid/Quatromer composite was prepared by mixing 20%

of the desired phospholipid by weight with 20%Quatromer solution in Toluene i.e. to
prepare a 5 gram solution of 20%(w/w) phospholipid/Quatromer composite, 200 mg of
desired phospholipid was added to 5 grams of 20%Quatromer in Toluene solution
(containing 1 gram of Quatromer and 4 grams of Toluene) (Appendix A). The mixture is
then stirred on a magnetic stirrer for 15 minutes for the phospholipid to mix
homogenously with the polymer. After the mixture is ready, the dog-bone Quatromer
samples were dipped in the 20% phopsholipid/Quatromer solution for a period of 3-10
seconds. The dipped specimens were then dried in an oven at 50"C for 1 hour. The pull
out velocity for the process was in a range of 4.5-15 mm/sec and the thickness of the
samples was ranging from 15-30 pim. The results for the dipping process varied for each
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batch as the process was performed manually and there was no automation involved to
control the pull out velocity as well as the dipping time.

11

Figure 3.1 Dipping coating phospholipid modification process for Quatromer
(Image Courtesy of http://www.solgel.com/articles/Nov00/mennig.htm)
The second method of modification of Quatromer with phospholipid involved a
process of mixing the phospholipid with Quatromer by weight to prepare
phospholipid/Quatromer composite. A 3% phospholipid/Quatromer

a

composite was

prepared by mixing 3% of phospholipid by weight with a 20% Quatromer solution in
Toluene (Appendix A) i.e. to prepare a 3% phospholipid/Quatromer composite, 30 mg of
desired phospholipid was added to 5 grams of 20%Quatromer in Toluene solution
(containing 1 gram of Quatromer and 4 grams of Toluene) . The 3% mixture was selected
as studies have shown that that 3% phospholipid concentration in polymer material is an
optimum amount required to distribute the phospholipid homogeneously throughout the
polymer, and imparting hemocompatibility properties (Lin-Yue et al,1997; Muhannad
Jumaa et al. 2000). The mixture prepared is poured into a rectangular cavity plate
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assembly (Figure 3.2) to from rectangular specimens (Appendix A). The plate assembly
was then allowed to dry in an oven at 50"C for 3 hours.
For all the mechanical, surface characterization, and platelet adhesion tests
performed, only the 3% phospholipid/Quatromer composite samples were used in the
tests while none of the samples fabricated using the 20% phospholipid/Quatromer
dipping process were used to perform any of the above tests. Prior to performing all the
mechanical tests, surface characterization tests, and platelet adhesion tests, it was
determined that the phase mixing technique has more advantages than the dipping
process, and hence, all the various tests were performed with the samples fabricated using
the 3% phospholipid/Quatromer phase mixing technique. The details for selecting the
phase mixing process over the dipping process are presented later in the discussion
section.

3.3

Mechanical Testing
The

mechanical

testing phase included three different types of testing i.e. tensile

testing, peeling strength test, and shear strength test. The tensile tests were performed to
determine the stress strain data for Quatromer and the six modified Quatromers as well as
to determine the tensile strength of different concentrations of phospholipid/Quatromer
composites. The peeling and shear strength tests were performed to determine the
tackiness or stickiness as well as the surface (rough or smooth) of Quatromer and the
phospholipid modified Quatromer.
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3.3.1

Dog-bone specimen preparation
Dog bone shaped specimens were prepared for Quatromer as well as for six

different phospholipid modified polymers to perform the mechanical tests (Appendix A).
A 20% Quatromer solution was used to prepare the specimens. The Quatromer solution
was prepared by mixing 20% of Quatromer pellets in 80% of Toluene solvent by weight.
The mixture was then stirred on a magnetic plate for 2-3 hours. Before making the
solution, the Quatromer pellets were dried overnight at 70"C in an oven. A stainless steel
three-plate assembly was used to cast the polymer solution into rectangular specimens.
The plate assembly basically consisted of three components i.e. a stainless steel bottom
plate for support, brass gaskets of 0.3 mm thickness, having a rectangular cavity in the
center, and stainless steel blocks, also having rectangular cavities in the center which are
of the same dimensions as those in the brass gaskets. The brass gaskets were placed on
the top of the bottom plate and then the stainless steel blocks were kept on top of the
gaskets in such a way that the cavities in each of them were coincident with each other.
The three components were held in place by tightening them with six #4-40 screws.
Before pouring the solution in the cavities, the cavities were cleaned with alcohol to
remove any impurities present on the surface. Experiments were carried out to determine
the relation between the quantity of solution poured in the cavity and the specimen
thickness, showed that 5 mL of solution gave a desired thickness of 0.3 mm. Hence, 5 mL
of polymer solution was poured in each of the cavities and the plate assembly was then
placed in an oven at 70"C for four hours. After the samples were dried, they were
removed carefully from the plate. A dog-bone shaped steel cutting dye and a hammer was
used to slice the rectangular specimens into dog-bone specimens according to a modified
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version of ASTM standard D 638-89. The cutting process was then followed by a
specimen examination process where the thickness of each of the specimens was
measured. The specimens were measured at the two ends as well as in the center, and an
average of all the three measurements was recorded. Specimens with average thickness of
0.3mm were considered while the ones with a thickness variation of more than 10% were
discarded.

Figure 3.2 Three-plate assembly used to mold rectangular specimens for mechanical tests
and dog bone specimen dimensions
3.3.2

Tensile testing
Two sets of tensile tests were performed. The first tensile test was carried out to

compare the stress strain data between the Quatromer, and the six different phospholipid
modified Quatromers. The second test was performed to evaluate the change in tensile
strength by varying the percent weight of phospholipid in Quatromer. The tensile tests of

Quatromer and the modified ones were carried out using an ElectroforceTM (ELF) 3200
materials tester (Enduratec Systems Corp., Minnetonka, MN). The tensile tests of all the
materials were performed according to ASTM standards D 882 - 88 (thin plastic sheets),
and D 3039 - 89 (composites). For each sample, at least five specimens were tested. The
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dog-bone specimens with thickness of 0.3

0.01 mm were clamped to grips of the

machine and were pulled at a speed of 5 m

min. The results from the tests helped in

providing stress strain data i.e. ultimate tensile stress (UTS), ultimate strain (US), and
Young's Modulus (E).

Figure 3.3 EnduraTec ElectroforceTM (ELF) 3200 materials tester

3.3.3

Peeling Test
The peeling test is a secondary and an additional test performed to determine the

effect of phospholipid modification on the stickiness as well as the interfacial adhesion
between two Quatromer as well as two modified Quatromer surfaces. The peeling tests
were carried out according to ASTM standard D 903- 98 (Peeling or Strip test). A Tpeel test was performed where the angle of peeling was 90 degrees. For the peeling test,
two 30 mm long and 0.3 mm thick rectangular strips were prepared using the plate
assembly and the polymer strips were then casted on each other over a contact length of
25mm. The top layer of the polymer was laid on the bottom layer in such a way that no
air bubbles were trapped between them. One free end of each of the strips was held by the
two action grips of the Enduratec machine and was pulled at a rate of 5mm/min force.
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The test helped in determining the peel force required to separate the two strips of
Quatromer as well as modified Quatromer polymer.

Figure 3.4 Specimen arrangement on Enduratec machine for the Peeling test
3.3.4

Shear Strength Test
The shear strength test is also an additional test performed to evaluate the

stickiness and interfacial adhesion forces for plain Quatromer and phospholipid modified
Quatromer. The shear strength test was carried out according to ASTM standard D 532192 (Interface Shear test). A 180-degree shear bond strength test was performed. Two
rectangular polymer strips 0.3 mm thickness and 30 mm length were prepared using the
plate assembly and the strips were then cast on each other over a contact length of 10
mm. The two free ends of the specimens were then pulled at rate of 5mm/mi

by the

action grids. The tests helped in determining the interfacial forces between the two
polymer surfaces.

Figure 3.5 Specimen arrangement on the Enduratec machine for shear strength test
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3.4

Surface Analysis
The

surface

characterization

or surface

measurements of contact angle, surface energy, the

analysis

O/C

study

consists

of the

ratio, and the surface texture.

The contact angle and surface energy measurements help evaluate the hydrophobicity the

Quatromer surface and different phospholipid modified polymers. The 0/C ratio study of
the biomaterials help analyze the oxygen content as well as the number of carbonyl
groups present on the surface which correlate with the number of negatively charged sites
and endothelial cell growth on the surface (Ertel 1990).

3.4.1

Contact Angle Measurement
Contact angle measurements of liquids on polymer surfaces are one of the most

widely used methods to determine the hydrophilicity and the adhesion properties of
solids. The contact angle measurement test was performed according to the ASTM
standard D5946-96 (Polymer films). The contact angle or wetting angle is the one
included between the tangent plane to the surface of the liquid and the tangent plane to
the surface of the solid, at a point of contact. For these experiments, the liquid used to
measure the contact angle on the polymer surface was distilled water. The contact angle
experiments were performed using distill water rather than other liquids such as blood
and alcohols, as using blood would have involved complications related to coagulation
(requiring anticoagulants) while alcohols may induce chemical reaction with the
Quatromer surface. Also, distill water is one of the

most

standard and most referenced

liquid used for contact angle measurements. The contact angle was measured using a
laboratory microscope fitted with an assembly. The assembly basically constituted of a
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stage mounted with a triangular glass prism and a glass slide held by two pins. The
specimen was kept on the glass slide and a drop of distilled water was placed on the
specimen. A TV monitor was connected to the microscope, which helped to show the
picture of the drop on the specimen surface. The light from the source passed through the
drop of liquid and then striked the prism, which in tum refracted the path of the light to
the lenses. The microscope has a 3600 scale, which helped to measure the contact angle
of the specimen.

Coiatact Anqie

Figure 3.6 Contact angle for a solid-liquid interface (Image courtesy of ht-://wwwndted.org/EducationResources/CommunityCollege/PenetrantTest/PTMaterials/surfaceenerg
.htm)

Figure 3.7 Laboratory microscope fitted with a prism for contact angle measurerments
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The contact angle for a substrate can be measured using the below equation:
YSV =YLV cosO+7SL

where, YSV

I

YLV

YSL = int erfacialenrgiesof the solid / vapor,liquid / vapor,
Y

solid I liquid interfaces
O = contactangle
(3.1)
3.4.2

Surface Energy
The surface energy or surface tension at the liquid-solid interface is the measure

of forces of attraction at the liquid-solid interface. The surface tension study was carried
out according to the ASTM standard D2578-84 (Surface Tension test). The surface
energy test was carried out using commercially available Dyne Pens (UV process supply,
INC, Chicago, IL). A dyne pen is basically a pen filled with a fluid having a particular
surface energy. The dyne pens come in sets where the pens have dyne levels or surface
energy levels ranging from 30-68dynes/cm. In order to determine the surface energy, the
polymer specimen is placed on a level surface and then the lowest level pen is selected.
The tip of the pen is firmly pressed against the surface of the specimen, and a thin line is
drawn with the ink from the pen. If the ink line breaks into droplets within 2 seconds then
the surface has a surface energy similar or less than the ink, but if the liquid does not
break into droplets within 2 seconds then the same procedure is repeated with a higher
level dyne pen. Hence, the procedure is repeated with the next higher-level dyne pen till
the ink line on the surface breaks into droplets within 2 seconds. When the surface shows
beading of the ink, the value of the surface energy of the ink pen used is accepted as the
surface energy of the specimen. This procedure is followed at five different sites on the

specimen.
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Figure 3.8 Dyne ink marks on a surface and a Dyne pen set (Image courtesy of fcservice.net/dyne test marker! and http://www.uvprocess.co
products)

3.4.3

O/C ratio
The surface elemental composition study was performed to determine the Oxygen

(0), Carbon (C), Phosphorous (P), and Sulfur (S) percentage compositions in Quatromer
as well as the six different phospholipid modified Quatromers. The study was carried out
using a JSM-5900-LV scanning electron microscope (Jeol, Peabody, MA). Due to
limitations with the SEM-EDS system such as calibration for elemental carbon, the study
was initially planned to be carried out using an ESCA (Energy Spectroscopy for
Chemical Analysis) system, however due to some technical issues with ESCA, the study
had to be performed using the SEM-EDS system.
Each of the specimens was prepared in form of small round circles of 10 mm
diameter and was placed in the SEM chamber. Once, the samples are placed in the
chamber, the SEM scans the surface of the sample using an electron beam. As, the
electron beam moves over the sample surface it generates X-ray fluorescence from the
atoms in its path. The energy of each of the X-ray photon is collected using the EDS
(Energy Dispersive X-ray Spectroscopy) microanalysis system. Each element is said to
have a characteristic X-ray photon energy and thus, the EDS system plots the X-rays
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according to their energy and identifies the elements responsible for the peaks in the
energy distribution. The data output shows characteristic peaks for each element present
on the surface of the sample.

Figure 3.9 JSM-5900-LV scanning electron microscope for surface analysis of specimens
(Image courtesy of http://www.fiu.edu/~emlab/inst SEM.html)
3.5

Comparative Thrombogenic study
The comparative thrombogenic test or the platelet adhesion study was performed

to determine the effect of material, flow, and time on platelet deposition. The studies
were carried out using Quatromer, PC, EPC, DOPC, DDPC, DAPC, DMPC modified
Quatromers, and Sylgard (Dow Coming, Midland, MI) as control. Human blood labeled
with Mepacrine dye (Appendix B) having fluorophore-attached platelets was used as the
working fluid. A parallel plate flow chamber (Appendix D) was fabricated to allow for a
two-dimensional study of blood flow over a test sample and a control, under physiologic
flow conditions. The components of the flow chamber included a Lexan top plate, which
allows for blood flow, and an aluminum bottom plate embedded with the specimen. The
top Lexan plate has a blood flow channel with dimensions of 0.5mm x 5mm x 71mm
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which is connected by two inlet and two outlet openings having a diameter of 0.0625
inches. The bottom plate is fabricated from aluminum for added support. The bottom
aluminum plate had a rectangular cavity in the center having dimensions of 0.5mm
25mm

x

x

75mm which allowed a glass slide to be fitted in it. The test sample and the

control i.e. sylgard were cured on the glass slide. First the polymer was cured on one
third of the slide and then the sylgard was allowed to dry on the remaining two thirds of
the same glass slide. A polymer thickness of about 0.3 mm was achieved by pouring 3.8
grams on the glass slide and then 0.75 grams of sylgard was poured on the remaining
portion of the slide to achieve a matching thickness of 0.3 mm. The sylgard was allowed
to cure on the bottom plate for 24 hours. Once the bottom plate was ready, a thin layer of
sylgard was applied around the blood flow channel on the top plate to prevent any
leakage of blood. The top and bottom plates were then coupled together using 14 #4-40
flat head screws. The sylgard in the chamber was then allowed to cure for another 24
hours. The sylgard on the top Lexan plate was allowed to cure in the closed chamber to
render it air tight thereby preventing any leakage of blood during the experiments. The
chamber was placed on the fluorescent microscope stage in such a way that the sylgard
on the glass slide was close to the inlet of the chamber while the polymer was towards the
outlet. The chamber was placed in such a way in order to ensure that a fully developed
laminar flow was flowing over the polymer layer and the latter portion of the sylgard.
Two thin colored paper strips of 10 mm were attached to the outer surface of the
glass slide on the sylgard and the polymer portion to act as markers for taking readings at
the same points. Six sequences were recorded at the four ends as well as at the center in
between the endpoints of the colored strip for sylgard and the polymer. Three steady flow

49

rates of 10 s- (low), 100 s- (medium), and 1000 s- (high) and two pulsatile flow rates of
100 s- (medium), and 1000 s-1 (high) were used in the experiment.

Figure 3.10 Blood flow in the top plate and the arrangement of specimen on the bottom
plate
For each experiment, 150mL of human blood was collected into three syringes.
The blood was then transferred to a plastic bottle covered by an aluminum foil. The blood
was mixed with 150pL of Mepacrine dye and then the bottle was gently inverted few
times to mix the platelets with the Mepacrine dye (Appendix C). The blood was divided
into eight equal parts to run each of the eight chambers having the Quatromer, the six
phospholipid modified Quatromers, and Sylgard. Each of the chambers was run for a
period of 30 minutes and pictures were obtained at 5, 15 and 25 minutes for the sample
and the control. The samples were photographed using a Nikon Eclipse TS-100
Fluorescence microscopy (Nikon Inc, Melville, NY) and the frames were averaged at a
particular time using the Image Pro Plus 4.5 software (Media Cybernetics Inc, CA).
OH 3

Figure

3.11 Structure
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of Mepacrine

3.5.1

Laminar Flow Calculations
In order to minimize the platelet activation in the flow loop and obtain a fully

developed laminar flow over the test specimen, the equations below were used to

calculate the various dimensions of the flow chamber and the tubing. The equations were
based on a flow between two infinite parallel plates.

Q

P

1

-

3

(3.2)

ax

-12p

l

where, Q = Volume flow rate,l = unit depth

The shear rate was given as:
du

_

aP

a

2y 1]

dy2,cco
where,

du
-

dy

a2

a

3.3)

= shear rate,l = width of chamber, a = height of chamber

As the shear rate at the walls is zero, y is zero; hence substituting equation 1 in equation 2
gives
du

Q

6

dy

l

a

1

2y

(34)

a

a

The equation for the entrance length developed by Fox is as followed:
L

S=0.06R = 0 . 0 6

pVD_

pVD

Dp

where, V -

=

A

average velocity, p = blood viscosity, p = blood density, and

(3.5)

A
P

D =4-=hydraulic diameter
The above equation shows that the

maximum

entrance length is proportional to

the flow rate, which in turn is directly proportional to the shear rate. Hence, the maximum

51

entrance length calculated for the high shear rate (1000 s-) i.e. 1.43 mm was used in the
construction of the flow chambers.
The shear rate within the tubing was calculated in order to verify that the tubing
had a lower shear rate than the chamber. The following set of equations was used to
calculate the shear rate within the tubing.

A

8rr
p

(3.6)

x

where, V = average velocity

The point at which the maximum velocity is achieved is calculated as:
du

dr

1 aP
2/pax

(

Hence, substituting equation 3 in equation 4 gives the wall shear rate as:

du
dr
dr

-4V
r

(3.8)

r

The shear rate for the tubing was found out to be 518 s , which is half of that in
the flow chamber i.e. 1000

s-.

The lower shear rate in the tube helped ensure minimum

platelet activation in the flow loop.

3.5.2

Human Subject Participation and Blood Withdrawal
For each experiment, healthy, normal subjects who did not take any alcohol,

aspirin, and Vitamin

E were

selected to donate blood. The blood was drawn by a licensed

phlebotomist using venipuncture. A blood flyer was used to attract the donors (Appendix
B). An IRB (Institutional Review Board) approval from the university was obtained, and
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the blood was drawn according to the guidelines laid by the IRB. All the participants
were required to sign an informed consent before drawing the blood (Appendix E).
For each experiment, 150 mL of human blood was drawn in three 60 mL syringes.
Each of the three syringes was first filled with 5 mL of heparin solution. The syringes
were then mixed with blood to collect 50 mL blood in all of them. The blood from the
three syringes was then emptied into a plastic bottle.

3.5.3

Blood Flow System
A closed flow loop connected using siliconee rubber tubing (Cole Parmer, Vernon

Hills, IL) was prepared to run blood through the chamber (Figure 3.13). A multi pass 30
min experiment was run to determine the effect of time on the deposition of platelets. The

fluorescence labeled blood was held in a reservoir, which was connected to a pump using
the siliconee tubing. A function generator attached to the peristaltic pump (Cole Parmer,
Vernon Hills, IL) helped in pushing the blood through the loop at the required flow rate
and a frequency of 1 Hz for pulsatile flow rates. The generator was not used for the
steady flow rates. For the steady flow experiments, a removable capacitance chamber was
connected to the pump to dampen out the oscillations in the flow. After passing the
capacitance chamber, the blood enters the chamber and then returns back to the reservoir.
The blood returned to the reservoir is recirculated in loop for 30 minutes (Figure 3.14).
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Figure 3.12 Blood Flow Loop for Comparative Platelet Adhesion tests

Figure 3.13 Flow chamber to run blood through the specimen surface
The flow chamber embedded with the sample is placed on the fluorescence
microscopy stage (Figure 3.14) and Mepacrine labeled blood is run through the chamber.
For these experiments, the fluorescence microscope Nikon Eclipse TS-100 Fluorescence
microscopy (Nikon Inc, Melville, NY) lens is connected with an AC UV light source.
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The UV light source helps illuminate the Mepacrine labeled platelets thereby allowing us
to see the platelet deposition on the polymer surface. The fluorescence microscope is
connected to the Streampix software (Norpix Inc, Montreal, Canada), which helps in
capturing real time platelet deposition sequences in Norpix Sequence File format. The

sequences are then converted to individual TIFF images for a particular time. The TIFF
images are then opened using the Image Pro Plus 4.5 software (Media Cybernetics Inc,

CA).

Figure 3.14 Flow loop setup with the flow chamber and Nikon Fluorescent microscope
3.5.4

Data Collection and Analysis
Norpix sequences acquired using the Streampix software for each samnple at a

particular time and for a particular shear rate are first converted to TIFF images. The
TIFF images are then averaged using the Image Pro Plus software. First of all, nine
focused frames were selected from a sequence recorded at location one (first end-point of
the colored strip attached on the outer surface of the glass slide) at a particular shear rate
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and 5 1 minutes for a specimen. The nine frames were averaged or integrated to obtain
one 9-averaged frame at the first location and at time 5 1 min. The same procedure was
repeated to obtain a single 9-averaged frame for the Sylgard (control) at the first location
point and 5 1 min time interval. The procedure was repeated to obtain average frames at
ten different locations surrounding the colored strip for the specimen as well as the
control for the first time interval of 5 1 minutes for a particular flow rate. The above
procedure was then repeated to obtain ten average frames for both the specimen and
Sylgard at two other time intervals of 15 1 min and 25 1 min respectively at the same

flow rate. The above procedure was used to obtain ten average frames for Quatromer,
Sylgard, and the six different modified Quatromers at five different flow rates. For
example, Figure 3.15 shows a single 9-averaged frame obtained using the ImagePro
software where nine focused frames for Quatromer at time 5 1 minutes were averaged.
The averaging of the frames was required to normalize the errors caused by the AC light
source. The AC light source causes fluctuation in light intensity in each frame and hence,
there is different light intensity for each of the nine focused frames. Thus in order to
normalize the light intensity in each of the nine focused frames, averaging or integration
of the frames is carried out to obtain one normalized average frame for each sample at a
particular location. The averaging or integration of images is performed to reduce the
noise in the image. It has also been found that the presence of AC source results in more
brightness in the center of the frame while the comers are darker. Thus, integrating all the
nine individual frames helps in obtaining a single integrated frame, which has normalized
intensity level throughout the frame. After, the averaging of frames is performed'; the
average frames for each interval were obtained and inputted in a MATLAB program
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(Appendix F). For each interval time, the average frame for the specimen at location one
was used as the sample while the corresponding Sylgard frame at location one and same
conditions was used as a reference. The output of the program helped to provide the
average platelet intensity value for the specimen at location one and at a particular time
interval for a specific flow rate. For example, a single 9-averaged frame of Quatromer at
time 5 1 min and location one was obtained as the test sample for the MATLAB
program while the corresponding Sylgard 9-averaged frame at 5 1 min and location one
was obtained as the reference image. The result obtained after running the MATLAB
program gave an average platelet intensity value for Quatromer at time 5 1 min and
location one. The above steps were repeated to obtain an average platelet intensity value
for the Quatromer at the remaining nine locations for time interval 5 1 min at a particular
shear rate. The same process was repeated to obtain ten average platelet intensity values
for Quatromer at 15 1 min and 25 1 min respectively at a particular shear rate. The
process was also repeated to obtain average platelet intensity values for Quatromer at five
different steady and pulsatile shear rates. Hence, the above mentioned steps were
repeated to obtain ten average platelet intensity values for Sylgard, and the six
phospholipid modified Quatromers at three different time intervals and five different
shear rates. The ten average values were used to obtain the mean and the standard error
values for each specimen at a given time interval and shear rate. One-way ANOVA tests
and post hoc Tukey tests were then performed using SPSS software to determine the
statistical significance of the results (Appendix G). For the statistical tests, results were
considered to be of significance if p :;0.05.
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Figure 3.15 Averaged Quatromer frame at 5 1 minutes

3.5.5

Microscope and Chamber Cleaning
The lens of the microscope was cleaned with a cotton swab dipped in a

commercially available Fisher optical lens cleaning solution before beginning the
experiment as well as after the completion of the experiment. After draining the blood
from the flow loop, the flow chamber was disassembled. Then the flow chamber and the
other accessories such as the reservoir, and the stainless steel parts were cleaned with a
solution of bleach, and tap water by soaking them for 30 minutes to disinfect them. Then
each of the components was rinsed with soap and tap water to remove any contamination.
The components were then scrubbed with ethyl alcohol pad and were then allowed to dry.
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CHAPTER

IV

RESULTS
4.0

Results
The result section is divided into mechanical test results, surface analysis results,

and the platelet adhesion tests. The first section presents the mechanical testing results,
which includes tensile test, peeling test, and shear strength test. The second part includes
surface analysis results such as contact angle, surface energy, and

o/C

ratio. The last

section of the study presents the comparative platelet adhesion results.

4.1

Sulfonation of Quatromer
The sulfonation of the Quatromer process was employed to identify its potential

in increasing the blood compatibility of the Quatromer. The methylene blue dye staining
test was carried out to determine if the sulfonation technique helped in successfully
creating sulfonate groups on the Quatromer surface. It was confirmed that when the
sulfonated polymer was dipped in methylene blue dye and then washed with distilled
water, the surface was stained blue, indicating the presence of sulfonate groups on the
Quatromer surface. The surface characterization of the sulfonated Quatromer showed that
the contact angle decreased from 74.340 30 (untreated Quatromer) to 68.23

2'

(sulfonated Quatromer). One of the interesting findings in the above study was that after
3-4 days, the dye test used to prove the presence of sulfonate groups on the surface did
not turn out to be positive. It was found that after 3-4 days of exposure of the sulfonated
surface to air, the methylene blue dye test did not stain the sulfonated surface blue. This
showed that the functional groups either became inactive or the surface reoriented.
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The surface characterization
sulfonated PC modified

of unsulfonated PC modified Quatromer and

Quatromer showed that the contact angle was

74 3' for both.

Hence, a phospholipid grafted sulfonated Quatromer showed the same surface results as
the one for phospholipid modified unsulfonated Quatromer which could be explained by
the bending of hydrocarbon phospholipid chains on the surface.

4.2

Mechanical Tests
The mechanical tests helped evaluate the tensile strength, surface roughness, and

tackiness for Quatromer and the six different phospholipid modified polymers.

4.2.1

Tensile Tests
Two different tensile tests were carried out. The first test was performed to

determine the comparative tensile strength between the Quatromer and the various
different phospholipid modified Quatromers while the second tensile test helped evaluate
the change in tensile test with variation in the %phospholipid concentration in the
Quatromer. Tensile tests were carried out to obtain stress-strain data for all the materials.
The stress vs. strain curve for

Quatromer,

3% PC + Quat, 3% EPC + Quat, 3% DDPC +

Quat, 3% DOPC + Quat, 3% DMPC + Quat, and 3% DAPC + Quat is shown in Figure
4.1. The Figure 4.1 shows that the Quatromer has higher tensile strength than all the
phopsholipid modified Quatromers. Hence, it can be observed that the mixing of
phospholipid with the Quatromer causes a decrease in the mechanical strength of the

Quatromer. The tensile strengths of all the different phospholipid modified polymers
were in a close range when compared to the Quatromer.
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Tensile Test
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Figure 4.1 Stress-Strain graph of Quatromer and different phospholipid modified
Quatromers
Table 4.1 Young's modulus (E), Tensile Stress (TS), and Number of specimens tested
(N) of Quatromer and six phospholipid modified Quatromers

Material

Modulus Of

Tensile Stress

Number of

Elasticity (E)

I(TS) at Strain

Specimens

(MPa)

E=O.45

(N)

(MPa

Quatromer
PC+ uat
[PC + Quat
DDPC+ Quat
DM PC+Quat
DAPC +Quat
DOPC +Quat

3.78
2.34

0.73
0.68

2.11

0.45

1.09
0.85

0.13
0.12
0.73 0.08
0.86 0.17
0.75 0.13
0.70 0.12
0.67 +0.14

2.26 0.96
1.96 0.73
1.76 +0.68
1.62 0.68

7
7
7
7
7
7
7

As shown in Table 4.1, the Quatromer had a tensile stress (TS) value of 1.09 MPa
while for the phospholipid modified Quatromers it was in the range of 0.67-0.86 MPa for
similar strain. All the different materials used for testing were found to have elongation
of more than 0.45mm/mm without any failure. The specimens could not be stretched
beyond that value, as the Enduratec machine is not capable of performing the test beyond
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that limit. The tensile stress values were obtained at a strain value of 6

0.45 MPa, and

hence the tensile stress values could not be represented as the ultimate tensile strength of
the samples. The Young's modulus of elasticity was calculated using the stress strain
values at the initial 10% of the strain. The Table 4.1 shows that the Young's modulus for
elasticity of Quatromer was higher than that obtained for the other phospholipid modified
Quatromers. The decrease in the elasticity of the Quatromer on mixing phospholipid can
possibly be explained by the phenomenon of plasticization, where the cross linked chains
disentangled on adding phospholipids, thereby reducing the modulus of elasticity of the
Quatromer.
A second tensile test was performed to determine the effect of increase in the percent
phospholipid content in the Quatromer. Figure 4.2 shows the stress strain data for

Quatromer, PC

3% +

Quat, and PC

15% +

Quat.

It can be observed from the graph that

the increase in the phospholipid concentration in the Quatromer leads to a decrease in the
tensile strength of the composite. Table 4.2 shows the Young's modulus, tensile stress,
and strain for the Quatromer and 3% as well as 15% phospholipid/Quatromer composites.
It can be observed that the modulus of elasticity of the Quatromer is almost 4 times that
of 15% PC modified Quatromer while the modulus of elasticity of 3% PC modified
Quatromer is more than twice that of 15% PC modified Quatromer. One of the possible
explanations for this phenomenon is that at 15% PC concentration in the polymer, a lot of
interlocked or crosslinked chains disentangled thereby resulting in a sharp decrease in the
elasticity of the polymer.
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Figure 4,2 Stress vs. Strain graph for different %phospholipid modified Quatromers
Table 4.2 Young's modulus (E), Tensile Stress (TS), and Number of specimens tested
(N) of Quatromer and different % phospholipid modified Quatromers.

Material

Modulus Of
Elasticity (E)
(MPa)

Tensile Stress
(TS) at Strain

(=0.45

Number of
Specimens
(N)

(MPa

Quatromer
PC 3% + Quat
PC 15% + Quat
4.2.2

3.78
2.34

0.73
0.68

1.09
0.83

0.13
0.12

7
7

0.96

0,45

0.42

0.08

7

Peeling Test
The peeling test was performed to determine the tackiness as well as the

interfacial adhesion forces for the Quatromer as well as PC modified Quatromer. Table
4.3 shows that the peeling test performed on two untreated Quatromer strips yielded a
peel force of 0.00037 N/im. The peeling test for PC modified Quatromer could not be
performed as the strips did not stick to each other and hence, there was significantly less
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adhesion between the PC modified surfaces. The difficulty of bonding two PC modified
surfaces show that they are siginificantly less tacky when compared with Quatromer
alone.
Table 4.3 Peeling force data for Quatromer and 3% Phosphatidylcholine modified
Quatromer

Material

Quatromer

Peeling

Force (N/rm)

Number of Specimens (N)

0.00037 0.0004

6

PC 3 % +Quat

4.2.3

6

Shear Test
The shear test was also performed to determine the interfacial adhesion force

between two layers of Quatromer as well as two layers of PC modified Quatromer. The
shear strength for the Quatromer was determined to be 0.00211 N/i

while the shear force

for the PC modified Quatromer was 0.000545 N/i (Table 4.4). Hence, it can be observed
that the interfacial shear force required to separate two Quatromer surfaces is almost four
times more than that required to separate two PC modified Quatromer surfaces. Hence, it
can be found that PC modification of the Quatromer helps in decreasing the tackiness of
the polymer.
Table 4.4 Shear strength data for Quatromer and 3% Phosphatidylcholine modified
Quatromer
Material

uatromer
PC 3 % + Qat

Shear Force (N/im)

Number of Specimens (N)

0.00211 0.0004

6

0.000545 0.0005

6
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4.3

Surface Analysis
The surface analysis includes the contact angle, surface energy, and

O/C

ratio

measurements.
4.3.1

Contact angle and Surface Energy
The contact angle and surface energy measurements are correlated as they are

governed by the same forces of cohesion and adhesion. The decrease in contact angle is
directly related to the increase in the surface energy of the surface. Table 4.5 shows that
the different phospholipid modification of Quatromer decreases the contact angle as well
as increases the surface energy as compared to the untreated Quatromer. The contact
angles for PC +

Quat,

DOPC +

Quat,

DDPC + Quat, and DMPC + Quat were in the

range of 12-18" while that for EPC + Quat and DAPC + Quat were in the range of 31-38".
Table 4.5 Contact angle and surface energy data for Quatromer and six phospholipid

modified Quatromers
Material

Contact Angle Surface Energy
(Degrees)
(Dynes/cm)

Quatromer

74.34 3

36-38

Phosphatidylcholine + Quat

17.12 3

62-64

Ethanolaminephosphatidylcholine + Quat

37.34 4

52-54

1,2-Dirnyristoyl-rac-glycero-3-phosphocholine + Quat

12.24 3

62-64

1,2-Didodecanoyl-rac-glycero-3-phosphocholine + Quat

13.94 4

62-64

1,2-Dilinoleoyl-rac-glycero-3-phosphocholine + Quat

16.76 3

62-64

1,2-Diarachidonoyl-rac-glycero-3-phosphocholine + Quat

31.33 3

56-58

The above results show that the modification of the Quatromer with the
phospholipids increases the adhesion forces between the liquid and the solid polymer
surface thereby overcoming the cohesion forces within the liquid molecule.
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4.3.2

0/C ratio
The oxygen carbon ratio was measured to determine the amount of free oxygen as

well as determine the carbonyl groups in the untreated as well as the various phospholipid
modified Quatromers. It has been observed by Ertel that an increase in O/C ratio
produces higher oxygen content and carbonyl groups on the surface, which correlates
with an increase in the number of reactive negatively charged sites and enhanced
endothelial cell growth (Ertel 1990). Table 4.6 shows the

O/C ratio

for the Quatromer and

the six different phospholipid modified Quatromers.
Table 4.6 O/C ratio data for Quatromer and six phospholipid modified Quatromers

O/C ratio

Material
Quatromer

0.042

Phosphatidylcholine + Quat

0.061

Ethanolaminephosphatidylcholine + Quat

0.061

1,2-Dimyristoyl-rac-glycero-3-phosphocholine + Quat

0.069

1,2-Didodecanoyl-rac-glycero-3-phosphocholine +

Quat

1,2-Dilinoleoyl-rac-glycero-3-phosphocholine + Quat
1 ,2-Diarachidonoyl-rac-glycero-3-phosphocholine + Quat

0.062

0.064
0.061

The above results show that the Quatromer has less oxygen as well as a lower

O/C ratio than all of the phospholipid modified Quatromers. Hence, it can be said that the
phospholipid modification helps in increasing the carbonyl group concentration in the
Quatromer thereby increasing the number of negatively charged groups on the surface.
Table 4.6 shows that the Quatromer has an O/C ratio of 0.042, however, it is known that
the structure of Quatromer has no oxygen atoms present in it. One of the possible reasons
for this phenomenon is that the Quatromer surface might have adsorbed water vapor from
the atmosphere and this may have resulted in the presence of oxygen in the Quatromer.
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4.4

Comparative Thrombogenic Tests
The comparative thrombogenic tests helped determine the effect of material, flow,

and time on platelet adhesion on the untreated Quatromer, the control i.e. Sylgard, and
each of the six modified phospholipid Quatromers. The tests were carried out at three
different steady flow shear rates of 10 s-, 100 s', and 1000 s1, and two different pulsatile
flow shear rates of 100 s 1 , and 1000 s-.
In order to design a flow chamber and a flow loop, which would result in the
minimum platelet activation and laminar flow over the sample, proper tubing and blood
flow channel dimensions were calculated. The results from Table 4.7 below gives the
radius of the tubing and the minimum entrance length required for the chamber to have
laminar flow conditions with minimum platelet activation. The highest flow rate used in
the chamber was 12.50 mL/min or a shear rate of 1000 s1, which required a minimum
entrance length of 1.43 mm to generate laminar flow. The Masterflex L/S 14 tubing
(Cole-Parmer, Vernon Hills, IL) was selected as it generates a shear rate (518 s-) that is
almost half of that present in the flow chamber. This low shear rate in the tubing helps to
reduce the platelet activation.
Table 4.7 Laminar flow calculations for the flow chamber and tubing
Flow rate
(mL/mn)

du/dYchamber

0.21

16.80

1.25
12.50

100.00
1000.00

Rchamber

Vchamber

Lchamber

(cm/sec
0.40

2.38
23.80

(s)

rtube

(mm)

du/drtube
(s4)

0.14

0.02

8.70

0.80

0.83
8.33

0.14
1.43

51.80
518.00

4.74
47.37

Figures 4.3 and 4.4 below show Mepacrine labeled platelet deposition pictures for

Quatromer and DMPC modified Quatromer at 5 1 and 25 1 minutes respectively. It can
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be observed from figures 4.3 and 4.4 that the Quatromer has much higher platelet
deposition at times min and 25 1 min when compared to DMPC modified Quatromer at
the same times.

Figure 4.3 Fluorescent microscopy pictures of Quatromer surface at 5 min (left) and 25
min (right)

Figure 4.4 Fluorescent microscopy pictures of DMPC modified Quatromer surface at 5

min (left) and 25 min (right)

The average platelet intensity values obtained from the Matlab program are plotted in
the tables and figures below to show that the effect of material, shear rate, and time on
platelet adhesion and activation on the surface. The platelet deposition experiments were
performed for the control i.e. Sylgard, unmodified Quatromer, and six different
phospholipid modified Quatromers namely, PC + Quatromer, EPC + Quatromer, DDPC
+

Quatromer, DMPC

+

Quatromer,

DOPC +
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Quatromer,

and DAPC +

Quatromer. Five

different shear rates i.e. steady low (10 s-), steady medium (100 s-), and steady high
(1000 s-), pulsatile medium (100 s®1), and pulsatile high (100 s-) and three different time
periods i.e. 5 1 min, 15 1 min, 25 1

in were used to evaluate the samples.

Tables 4.8, 4.9, 4.10 and Figures 4.5, 4.6, 4.7 shows the platelet intensity data at low,
medium, and high steady shear rates, while Tables 4.11, 4.12 and Figures 4.9, 4.9 shows
the platelet intensity at medium and high pulsatile shear rates. The results at all shear
rates show that the platelet intensity is the highest for the Quatromer while the control i.e.
Sylgard also had a high platelet deposition on the surface. The platelet intensity data also
shows that the

Quatromer

and the control i.e. Sylgard have much higher platelet

deposition than any of the phospholipid modified Quatromers while the DDPC, DMPC,
PC, and the DOPC modified Quatromers have lowest platelet deposition. Also, it was
observed that the platelet deposition increased for all specimens with time. It was found
that the platelet deposition was significantly high especially for Quatromer and Sylgard at
the high (1000 s-)

steady and pulsatile shear rates when compared to low and medium

shear rates.
Tables 4.13, 4.14, 4.15 and Figures 4.10, 4.11, 4.12 shows the platelet density at 5 1
min, 15 1 min, and 25 1 min respectively for Sylgard, Quatromer and different modified

Quatromers at different steady and pulsatile shear rates. The comparison carried out in
the above figures show that the platelet deposition at steady and pulsatile shear rates did
not demonstrate any significant differences. Tables E1, F2, F3, F4, F5, and F6 (Appendix
G) show the One-way ANOVA and post hoc tests for all the samples at different shear
rates. One-way ANOVA and post hoc Tukey tests (Appendix G) performed showed that

69

the PC DMPC, and DDPC modified Quatromers had the lowest platelet adhesion with
no significant difference for different shear rates.
Table 4.8 Platelet Intensity for Sylgard (control), Quatromer and different phospholipid
modified

Quatromers at Steady low shear rate
Time

Material

interval

Slygard
Quat
PC+Q
EPC+Q
DMPC+Q
DDPC+
DOPC+Q

5 1 min
15.44 1.21
19.71+1.95
3.16 1.52
8.52 1.37
2.44t1.12
2.49 1.51
5.12 1.24

15 1 min
21.73 2.35
30.30+3.55
4.33 1.12
11.72 1.71
4,11+1.82
3.78 1.75
6.78 1.51

25 1 min
41.13+3.73
42.68 2.77
6.24 1.95
13.34 1.92
4.77 1.39
4.43 1.15
7.58 2.33

DAPC+Q

7.24 1.61.

9.21 1.85

10.72 2.36

Platelet In

ensi1

(P1) For Steady LOW

Shear rate

10s'

50
45
40

S30
25

15mrn
-O25mrn

20-

10

Slygard

Quat

PC+Q

EPC+Q

DMPC+Q

DDPC+Q

DOPC+Q

DAPC+Q

Material

Figure 4.5 Platelet Intensity for Sylgard (control), Quatromer and different phospholipid
modified Quatromers at Steady low shear rate
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Table 4.9 Platelet Intensity for Sylgard (control), Quatromer and different phospholipid
modified Quatromers at Steady medium shear rate

Time interval

Material
Sl

ard

Quat Q
PC+Q
EPC+Q
DMPC+
DDPC+Q

5 1 min
13.38 1.92
23.43 1.48
4.77 1.01
8.67+1.16
3.13 1.25
4.23 1.41

15 1 min
19.732.84
28.34 4.17
6.64 2.32
10.99 1.66
4.74 0.98
6.61 1.34

25 1 min
39.58 2.41
42.13 3.16
7.14 1.94
14.32 1.87
6.31 1.27
7.62 1.84

4.92 1.53
7.39 2.22

5.52 2.23
10.80 1.72

6.72 1.43
12.52 2.85

DOPC+Q
DAPC+

Platelet ntensity (P1 for Steady Medium Shear rate 100S
50
45
40

35
30
15flmin

25
202

10

S ygard

Quat

PC+Q

EPC+Q

DMPC+Q

DDPC+Q

DOPC+Q

OAPC+Q

Material

Figure 4.6 Platelet Intensity for Sylgard (control), Quatromer and different phospholipid
modified Quatromers at Steady medium shear rate
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Table 4.10 Platelet Intensity for Sylgard (control), Quatromer and different phospholipid
modified

Quatromers at Steady high shear rate
Time

Material

1 m

Slyard
Quat

25 1

in

min

19.42 2.90

36.73 2.13

53.99 1.33

3.45
1.72
1.17
0.72

40,28 2.84
7.34+1.32
10.87 1.54
3.51+1.32

53.18 1.64

4.78 1.57

5.12 1.35

30.43
5.97
8.28
.84

PC+Q
EPC+Q
DMPC+Q

interval

151

DPC+Q

3.15 1.19

DOPC+Q

7.83 1.45
12.73 1.52
4.66 1.29

3.12
.714
1.04 _4AC 4.52
58 1.69
.81.219

DAPC+Q

15.80 298

9.27 1.47

Plate et ntmn

y e

oraPSteady HighShear rate

6.98 2.39

85219

100

60

P

40

E5mini
R25mn

0
20rn

10

S ygard

Quat

PC+Q

EPC+Q

DMPC+Q DDPC+Q

DOPC+Q

DAPC+Q

Material

Figure 4.7 Platelet Intensiy for Sylgard (control), Quatromner and different phospholipid
modified Quatromners at Steady high shear rate
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Table 4.11 Platelet Intensity for Sylgard (control), Quatromer and different phospholipid
modified Quatromers at Pulsatile medium shear rate

Material

5

Time interval
11
mm

m

5 1

i

Slygard
uat Q

12.21 1.93
21.92 1.26

24.73 3.35
31.22 2.54

37.17 2.92
39.67 3.55

PC+Q
EPC+Q
DMPC+Q

4.16 1.21
7.58 1.16
4.34 0.63

4.83 1.46
8.98 2.26
4.89 1.34

6.15 1.29
10.12 1.35
5.67 1.31

DDPC+Q

3.18 1.11

4.61 1.65

5.23 1.43

DOPC+Q

5.52 1.77

6.53 1.52

7.18 3.03

DAPC+Q

7.78 1.21

9.80 2,23

11.61 1.96

Platelet

Intensity

Pt for Pulsatil

Medlum Shear rate

100

s

40

p 30
20--

-m

S ygard

Quat

PC+Q

EPC+Q DMPC+Q
Materiai

DDPC+Q

OOPC+Q

DAPC+Q

Figure 4.8 Platelet Intensity for Sylgard (control), Quatromer and different phospholipid
modified Quatromers at Pulsatile medium shear rate
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Table 4.12 Platelet Intensity for Sylgard (control), Quatromer and different phospholipid
modified Quatromers at Pulsatile high shear rate

Time

Material

interval

15 1 mm
39.73 2.55
42.54 3.85

25 1 mil
50.86 1.73
51.04 2.07

5.68 1.52

6.33 1.32

8.05 1.05

8.59 1.77

14.22 2.66

16.83 2.12

DMPC+Q
DPC+

2.76 1.52
2.88 1.04

5.31 1.32
3.82 1.07

6.69 1.24
4.19 1.35

DOPC+Q

5.14 1.34

7.37 2.02
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Figure 4.9 Platelet Intensiy for Sylgard (control), Quatromer and different phospholipid
modified Quatromers at Pulsatile high shear rate
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Table 4.13 Platelet Intensity for Sylgard (control), Quatromer and different phospholipid
modified

Quatromers at different shear rates for 5 1 min time interval

Shear rate s

Material
Slygard
uat
PC+Q
EPC+Q
DMPC+
DDPC+Q
DOPC+Q
DAPC+

LS

15.44 1.21
19.71
3.16
8.52
2.44
2.49
5.12
7.24

Poa

1.95
1.52
1.37
1.12
1.51
1.24
1.61

eet intensty

MS
13.38 1.92
23.43 1.48
4.77 1.01
8.67 1.16
3.13 1.25
4.23 1.41
4.92 1.53
7.39+2.22

US
19.42 2.90
30.43 3.45
5.97 1.72
8.28 1.17
2.84+0.72
3.15+1.19
3.12+1.04
9.27 1.47

MP

12.21 1.93
21.92
4.16
7.58
4.34
3.18
5.52
7.78

1.26
1.21
1.16
0.63
1.11
1.77
1.21

HP
22.14 2.21
27.05 1.95
5.68 1.52
8.59 1.77
2.76+1.52
2.88 1.04
5.14 1.34
10.24 1.81
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Figure 4.10 Platelet Intensity for Sylgard (control), Quatromer and different phospholipid
modified Quatromers at different shear rates for 5 1 mmn time interval
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Table 4.14 Platelet Intensity for Sylgard (control), Quatromer and different phospholipid
modified Quatromers at different shear rates for 15 1 min time interval

s

Materialrate

Slygard

Quat(Q)

LS
21.73 2.35
30.30 3.55

MS
19.73 2.84
28.34 4.17

HS
36.73 2.13
40.28 2.84

MP
24.73 3.35
31.22 2.54

HP
39.73 2.55
42.54 3.85

PC+Q

4.33 1.12

6.64 2.32

7.34 1.32

4.83 1.46

6.33 1.32

EPC+Q

11.72 1.71

10.99+1.66

10.87 1.54

8.98 2.26

14.22 2.66

DMPC+Q
DDPC+Q

4.11 1.82
3.78 1.75

4.74 0.98
6.61 1.34

3.51 1.32
4.78 1.57

4.89 1.34
4.61 1.65

5.31 1.32
3.82 1.07
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6.78 1.51
9.21 1.85
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Figure 4.11 Platelet Intensity for Sylgard (control), Quatromer and different phospholipid
modified Quatromers at different shear rates for 15 1 min time interval
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Table 4.15 Platelet Intensity for Sylgard (control), Quatromer and different phospholipid
modified Quatromers at different shear rates for 25 1 min time interval

Material
MaeilLS
Syard

NIS

PC+Q
EPC+Q
DMPC+Q

41.13
42.68
6.24
13.34
4.77

DDPC+Q
DOPC+Q
DPC+Q

4.43 1.15
7.58 2.33
10.72 2.36

Quat(Q)

3.73
2.77
1.95
1.92
1.39

39.58
42.13
7.14
14.32
6.31

2.41
3.16
1.94
1.87
1.27

7.62 1.84
6.72 1.43
12.52 2.85

Shear rate

sH

MP

HP

1.33
1.64
1.45
1.52
1.29

37.172.92
39.67 3.55
6.15 1.29
10.12 1.35
5.67 1.31

50.86 1.73
51.04 2.07
8.05 1.05
16.83 2.12
6.71+1.24

5.12 1.35
6.98 2.39
18.52 1.92

5.23 1.43
7.18 3.03
11.61 1.96

4.19 1.35
8.92 4.43
17.74 3.36
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12.73
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Figure 4.12 Platelet Intensity for Sylgard (control), Quatromer and different phospholipid
modified Quatromers at different shear rates for 25 1 min time interval
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CHAPTER

V

DISCUSSIONS
5.0

Discussions

5.1

Is Sulfonation of Quatromer required?
The sulfonation of Quatromer was employed to identify its role in enhancing the

Quatromer's material properties. It is known that the Quatromer is highly stable and does
not have any free functional groups on the surface and hence, there are no surface charges
on the Quatromer surface. Hence, the sulfonation of Quatromer was employed to
generate functional groups such as SO on the surface, which may help in rendering
surface charges to the Quatromer surface.
The results showed that after 2-3 days of exposure of the sulfonated Quatromer
surface with air, the methylene blue dye test was negative. One of the explanations for
this occurrence was that the sulfonate groups on the surface became inverted or
reoriented towards the inside when exposed to the air. It has been observed that
functional groups such as sulfonates tend to show a pattern of reversibility when exposed
to air (Figure 5.1). The sulfonate groups tend to move towards the interior of the
Quatromer due to surface tension. This reorientation of the functional groups shows the
aging of the surface modification process. However, when the sulfonated

Quatromer

drenched in water, the functional groups tend to reorient towards the outside.
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is

Figure 5.1 Reversibility or aging of sulfonate fnctional groups in presence of air
Also, Quatromer modified with just phospholipid and Quatromer modified using
both sulfonation process as well as phospholipid had a similar contact angle of 74 30,
thereby showing the same surface analysis results. One of the possible reasons for this
phenomenon was that the phospholipid attached to the sulfonate groups had a bending of
their hydrophobic chains (Figure 5.2).
Even though results from the surface characterization of sulfonated Quatromer
showed that the contact angle or the surface properties did not have significant
imnprovements when comnpared to untreated Quatromer, yet the grafting of sulfonate
groups would play an important role in improving the Quatromer's implant properties.
The sulfonation of Quatromer would help reduce the tackiness of the Quatromer which is
desired in mnanufacturing of the valve, and would help form possible cross linkages to
reinforce the strength of the Quatromer. The sulfonation process would help in rendering
a homogenous surface as well as help to impart antimicrobial activity to the Quatromer
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surface, which may not be achieved just using phospholipid modification (Hee et al.

2000).

Figure 5.2 Sulfonation of Quatromer and phospholipid grafting on sulfonated
5.2

Quatromer

Surface modification vs. phase mixing modification of Quatromer
Two types of

modification

processes were used to attach phospholipid to the

Quatromer surface. The first method was surface modification, which was achieved by
dipping the untreated Quatromer surfaces in 20% phospholipid/ Quatromer solution. The
other method, which was more of structural modification, involved mixing of 3%
phospholipid to the

Quatromer

by weight. Surface modification of Quatromer using dip

coating is an easy, relatively inexpensive, and quick method; however it suffers from
many disadvantages when compared to phase
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mixing

of phospholipid with the

Quatromer. One of the major disadvantages of the dipping process was the lack of strong
attachment of the phospholipid groups to the Quatromer surface. Preliminary experiments
carried out in the Cardiovascular Engineering lab (CVEC,

Florida International

University) showed that when a Quatromer substrate was dipped in additional Quatromer
solution, peeling occurred between the new layer formed and the Quatromer substrate.
This showed that the dip coating lacked the ability to allow stronger attachment of the
surfactant layer onto the Quatromer surface. This drawback of the dipping process would
result in a very small layer of phospholipids on the

Quatromer

surface. The small

superficial layer of phospholipid formed on the Quatromer surface may limit or interfere
with the self-assembling of the phospholipids into bilayers. The absence of the bilayers in
the Quatromer may detrimentally affect the blood compatibility properties of the
Quatromer, as the highly ordered bilayers as shown in this thesis enhance the
hemocompatibility of the polymer. Studies performed by van der Heiden using DOPC on
polyurethanes showed that the presence of mere phosphatidylcholine groups on the
polyurethane surface was not sufficient to suppress protein adsorption, rather the highly
ordered structure of phospholipid bilayers is much more effective in suppressing the
protein adsorption (van der Heiden AP et al, 1998). In the case of a phase mixture of a
3% phospholipid/Quatromer by weight, the phospholipids are believed to be distributed
homogeneously throughout the Quatromer material and the phospholipid has the ability
to self assemble to form bilayers inside the polymer body (Figure 5.3). Another drawback
of surface modification is that the layer of phospholipid on Quatromer may have a limited
amount of phospholipid, which may detach or suffer oxidation reactions forming free
radicals or peroxides with time. However, in a 3%
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phase phospholipid/Quatromer

mixture, the phospholipids would keep migrating towards the surface by the means of
passive diffusion, replacing those on the surface that may become detached or are
destroyed (Figure 5.3). Thus, in an implantable device such as a heart valve, which is in
human body for 7-10 years, the phospholipid/polymer phase

mixture

would be

advantageous, as there would be constant migration of phospholipids towards the surface

providing the polymer with a longer lasting hemocompatible surface.

Figure 5.3 Phospholipid orientation in phase ixed Quatromer (top) and a surface
modified Quatromer (bottom)
Another

major

drawback faced by traditional dip coating

method

is that the

surfactant distribution on the polymer surface would be difficult to control, i.e., it
not be

uniform

may

and homogeneous. Traditional dip coating process causes a "wedge

effect" i.e. the filmn

thickness

varies fromn top to the

while curing the surface. For examnple, when

Quatromer leafi

Cardiovascular Engineering lab (CVEC, Florida
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bottom

International

as well as entraps bubbles
Ltere fabricated in the
University) by dipping the

mold in a 15% Quatromer solution, the leaflets tend to show a lot of bubbles trapped
inside them. Thus, dip coating process may result in sites on the Quatromer surface where
the PC coating is thin or absent. These sites may increase the potential of platelet
activation and adhesion. The failure to modify the surface uniformly may also result in
increased surface roughness. In contrast, a 3% phospholipid/Quatromer phase mixture
has sufficient phospholipid to distribute it homogeneously and uniformly within the bulk
material as well as on the surface. The mixing would also help in creating a much
smoother Quatromer surface.

5.3

Effect of phospholipid acyl chain unsaturation and length
The chain length and degree of unsaturation of the acyl or hydrocarbon chains in

phospholipid has a vital relationship with hydrophobicity of the surface and biological
effects. It has been found that saturated phospholipids tend to be less hydrophobic in
nature while the unsaturation of phospholipids tends to decrease hydrophilicity or
decrease water penetration from the polar group region (Subczynski 1994). The double
bond results in a kink in the hydrocarbon tail (Figure 5.4), which results in a disorder
conformation of the acyl chain. The kink in the tail prevents compact arrangement of the
phospholipids thereby decreasing the water penetration around the polar head group. It
has been observed that longer acyl chain lengths tend to increase the width of the central
hydrophobic regions of the hydrocarbon chains (Subczynski 1994). The increase in the
chain length is a minor contributor for the increased hydrophicity while the introduction
of double bond in the chain is the major contributor. Moreover, it has been found that the
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hydrophicity effect is more dominant due to the presence of a cis double bond rather than
a trans double bond (Subczynski 1994).
Experiments carried out by Akira Tokumura and group on Lysophosphatidic acid
(LPAs) showed a rank order for platelet aggregation potential for various saturated and

unsaturated LPAs having different chain lengths. The order for aggregating activity of
LPAs was 16:0>18:2>18:3>18:1>18:0>14:0>12:0 where the first digit represents the
number of carbon atoms while the second digit indicates the number of double bonds in
acyl chain (Tokumura 2002). The order shows that the shortest and saturated
phospholipids have the lowest platelet aggregating activity. This may be one of the
reasons for the lowest platelet intensity obtained for DMPC+Quat and DDPC+Quat
specimens. The DMPC and DDPC phospholipids used to modify the Quatromer have a
structure of 14:0 and 12:0 respectively. As observed in figure 5.4, unsaturated
phospholipids have a kink in the tail and this resulted in spaces in the bilayer. The
presence of these spaces results in increased protein associations, while a saturated
phospholipid has fatty acids sticking closer to each other thereby preventing any empty
spaces within the bilayer. Hence, unsaturation of the phospholipid hydrocarbon chains
may be a contributing factor in increased platelet adhesion.

Figure 5.4 Bilayer arrangements of a saturated (left) and an unsaturated (right)

phospholipid
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One of the important parts of this research was to determine the oxidation damage
of phospholipids due to aging. The acyl chain unsaturation has an important relationship
with the oxidation of the double bonds resulting in the formation of peroxides. The CH
bond in an unsaturated phospholipid is susceptible to spontaneous oxidation resulting in
formation of free radicals such as peroxides (Seelig 1977). These radicals are highly
unstable and they tend to increase the oxidation stress in the materials. Hence, highly
unsaturated phospholipids such as DAPC, which have arachidonate group having four
double bonds is highly susceptible to oxidation in the body and they may be destroyed
faster in vivo. Saturated phospholipids such as DDPC and DMPC that have no double
bonds in their hydrocarbon chains and hence, suffer from less oxidation reactions due to
the presence of a stable and ordered hydrocarbon tail structure. Also the addition of
ethanolamine to phospholipids has shown to decrease the oxidizability of CU bonds
(Maeba 2003). Hence, EPC+Q may help increase the oxidation resistance of the CH
bonds in the Quatromer.

Most of the unsaturated phospholipids have a cis double bond.

The cis double bonds are responsible for producing the kink in the hydrocarbon tail and
hence results in a loosely packed bilayer. This bilayer arrangement with spaces in it
results in greater oxidation of the CH bonds. In contrast, the presence of trans double
bond results in absence of a kink in the hydrocarbon tail as the hydrogen atoms of the
double bond are on either side of the fatty acid. The absence of the kink in the tail causes
them to behave similar to saturated fatty acids even though they are unsaturated. The
trans bond results in formation of a compact bilayer where the fatty acids are stuck close
to each other and this provides increased oxidation resistance (Elena, 2003). Hence
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addition of trans unsaturated phospholipids such as Sphingomyelin may also help
increase the oxidation resistance of the

Quatromer.

Temperature also plays an important role in affecting the properties of the
phospholipids. Studies perfonned have shown that an increase in unsaturation of the
phospholipids tend to lower their phase transition temperature Tm (Huang 1969). The
phase transition temperature Tm is the temperature at which the hydrocarbon chains in the
phospholipid undergo a change from an ordered state to a disordered state (Huang 1969).
In the ordered state the fatty acids in the phospholipids have a compact arrangement and
this tends to increase the hydrophilicity of the phospholipids. It has been observed that at
low temperatures (below T) the bilayers in phospholipids tend to have an ordered, and a
solid gel-like structure while at high temperatures (above Tm) the bilayers exist in a
disordered fluid state (Huang 1969).
Unsaturated phospholipids as explained earlier have a kink in their tails, and this
bending of the acyl chains is supposed to reduce the melting temperature Tm of the
phospholipids as the amount of interaction between the acyl chains decreases and this
subsequently increases the Gibbs free energy (Wang 1997). Trans double bonds as
compared to cis double bonds tend to increase the melting temperature of the
phospholipids as the acyl chains have greater contact between them (Wang 1997). Thus,
it can be observed that an increase in the temperature as well as unsaturation in the
phospholipids can possibly decrease the stability and the

melting

temperature of the

phospholipids, which in turn may affect its hydrophilic properties as well as structural
stability.
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5.4

Mechanical Testing
The mechanical testing of the Quatromer and the different PC modified

Quatromers was carried out to evaluate the effect of phospholipid modification on the
bulk properties of the polymer and the effect on the tackiness as well as the surface
texture of the polymer. The tensile test performed on the untreated Quatromer and the six
different PC modified Quatromers showed that the addition of phospholipids to the
Quatromer resulted in decrease in the tensile strength of the Quatromer. Also, the second
tensile test performed on untreated Quatromer and different %phospholipid/Quatromer
mixtures showed that the tensile strength decreased with increase in the %phospholipid
concentration in the Quatromer. The tensile tests show that the modulus of elasticity of
all the six different phospholipid modified Quatromers is almost half of that of untreated
Quatromer. One of the possible reasons for the decrease in the modulus of elasticity of
the Quatromer on adding a phospholipid is due to the phenomenon of plasticization. The
unmodified Quatromer structure has crosslinked or entangled hydrocarbon chains and the
addition of phospholipids to Quatromer tends to untangle the crosslinked chains. The
straightening or detangling of the hydrocarbon chains, known as plasticization, may
result in the decrease of the modulus of elasticity of the phospholipid modified

Quatromer. The tests performed using different %phospholipid concentrations in
Quatromer implied a direct relationship between an increase in the phospholipid
concentration and decrease in elastic modulus. One of the probable reasons of such a
huge decrease in the modulus of elasticity at 15% PC modification when compared to 3%
concentration is that at such a high PC concentration in the Quatromer, a large amount of
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crosslinked hydrocarbon chains may be detangled resulting in greater loss of the

modulus

of elasticity of the Quatromer.
The peeling and the shear strength tests were performed to determine the effect of
phospholipid on the tackiness of the Quatromer. The shear strength test showed that the
interfacial force required to separate Quatromer surfaces is four times higher than that
required for separating PC
be performed for PC

modified

surfaces attached together. The peeling test could not

modified surfaces

indicating that the surfaces lacked the tackiness to

attach to each other. Hence it can be proved that the tackiness of the Quatromer reduces
significantly with addition of phospholipids. The reduced tackiness for PC modified
surfaces can be explained by the fact that the PC modification results in a smooth surface.
The smooth surface helps reduce the anchorage (micro pits, cracks or material mounts)
sites on the surface thereby reducing the tackiness or stickiness of the Quatromer. The PC
modification also helps in imparting lubricity or reduced friction to the Quatromer
surface as the hydrophilic nature of the phospholipid creates a water interface or layer at
the

Quatromer surface,

thereby reducing wet friction on the surface.

The reduced stickiness of the

Quatromer

is desired for the ease of manufacturing

heart valve leaflets. The Quatromer is sticky and when the Quatromer leaflets are
fabricated using the mold, the Quatromer sticks to the mold and this causes empty voids
in the leaflets. To peel the Quatromer from the mold, it requires a process of adding
baking soda to remove the stickiness of the polymer and thus, modifying the Quatromer
with phospholipid helps reduce the stickiness of the Quatromer. The peeling and shear
strength tests show that the modified Quatromer is significantly less sticky and thus while

88

peeling the

modified Quatromer

leaflets from the mold; the polymer does not stick to the

mold thereby causing no voids in the leaflets.
5.5

Surface Analysis
The surface analysis of the Quatromer and PC modified Quatromer surfaces was

carried out to determine the hydrophilicity as well as the surface roughness of the
surfaces. The contact angle as well as the surface energy measurement studies showed
that the PC modification notably increased the surface hydrophilicity of the Quatromer
surface. The phosphate head groups tend to loosely bind water molecules on the surface
thereby increasing the wettability of the surface. The hydrophilic nature of the PC head
group possibly forms a thin water layer on the surface of the Quatromer thereby allowing
the body fluids to flow easily over it without activating the components in it.
The

O/C

carbon results obtained for the research study may not be accurate as

they were obtained using the EDS-SEM system. It is known that the EDS-SEM system is
not a good tool to determine the elemental composition of substrates, especially for
carbon determination due to potential drawbacks such as poor spectral resolution and
calibration of carbon. Thus, initially the study was supposed to be performed using an
ESCA (Electron Spectroscopy for Chemical Analysis) system at FIU; however, due to
some technical problems with the ESCA system, the

O/C ratio

study had to be performed

using the EDS-SEM system.
The O/C ratio was calculated in order to determine the increase in the amount of
oxygen as well as carbonyl groups on the Quatromer surface. The PC modification was
effective in increasing the 0/C content, which increased the negatively charged carbonyl
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groups on the surface. These negatively charged carbonyl groups present on the surface

may be

the main force in repelling the negatively charged platelets from attaching on the

Quatromer

surface. The carbonyl groups played an important role in enhancing the

hydrophilic nature of the Quatromer. The O/C ratio results showed the presence of
oxygen in

Quatromer;

however it is known that

Quatromer is composed of only carbon

and hydrogen atoms and no oxygen atoms. One of the possible reasons for this
phenomenon is that the Quatromer surface may have absorbed water vapor from the
atmosphere and the oxygen atoms present in the water vapor may have been responsible
for oxygen content observed in Quatromer during the SEM studies.

5.6

Comparative Platelet Studies
The comparative platelet adhesion tests were performed to determine the potential

of Quatromer as well as the different phospholipid modified Quatromers in activating and
attaching platelets on their surface over a period of time as well as at different shear
conditions. A multi-pass flow loop was used to determine the effect of time on the
surface properties of the material in activating the platelets. The multi-pass system helped
identify if the functional groups on the modified surface tend to show their effect over
time or if they suffered from various problems such as oxidation reactions, reorientation
of the functional groups or erosion. There were several sources in the experiments, which
may result in errors in the results. One of the sources is the use of a multi-pass system,
which would suffer from increased platelet activation due to the perturbing effects of the
peristaltic pump, yet as the study is a comparative evaluation of all the polymers, there is
a negligible impact on the conclusions. Also, the pictures obtained using the fluorescent
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microscopy used an AC light source and this resulted in more brightness in the center of
the frame while the edges were dark. Another source, which may cause error, is the
inability of the ImagePro software or the MATLAB program to differentiate between
Mepacrine labeled platelet aggregates and WBCs in the blood. Thus, when the flow loop
was run, both the WBCs as well as the platelets were observed in the frames and there
was no way the WBCs could be differentiated from the platelet aggregates. To overcome
these problems nine best-focused frames were selected at a single time and at the same
conditions for each material. The frames were then averaged using the ImagePro
software. The averaged frame for the material was then fed into the MATLAB program
with the corresponding average frame for the Sylgard as the reference. The result
obtained was an average value for the platelet intensity for the test material at a given
time and given flow condition. This averaging of the frames helped to decrease the errors
related to AC power source as well as the inability to differentiate between platelet
aggregates and WBCs. Moreover as the study was a comparative assessment for the
different polymers, the same errors were encountered in all the experiments and hence, it
was believed that the errors had a minimal effect on the conclusions.
The comparison between the various polymers and the control i.e. Sylgard was
carried out at steady and pulsatile shear rates and at three different time intervals of 5

1

min, 15 1 min, and 25 1 min at the same shear rate. The results for platelet deposition
on various polymer surfaces at different shear rates showed that there was a greater
platelet deposition at high shear rates (Figure 4.6 and Figure 4.8). Experiments carried
out on polyethylene (PE), polytetrafluoroethylene (PTFE), and siliconee rubber (SR),
have shown that the platelet adhesion increases with increase in the shear rate
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(Balasubramanian 2002). It was observed that the platelet intensity results at high
pulsaltile and high steady shear rates were higher at all times when compared with low
and medium pulsatile and steady shear rates. It was also found that for all of the flow
rates there was an increase in the platelet intensity with increase in the residence time.
Each of the shear rate showed that the platelet intensity increased from 5 1 min interval
to 25 1 min time interval. Experiments performed on polymer surfaces show that the
platelet deposition increases with increase in the residence time (Balasubramanian 2002).
One of the flow chambers was allowed to run for one hour and it was observed that the
platelet intensity on the surface did not increase significantly, showing that the platelet
deposition reached a maximum or a plateau after a certain amount of time. When the
results for pulsatile and steady shear rates were compared, it was found that the results for
both were same and had no significant differences at a given time interval. It was studied
by Blusestein etal. (2000) that pulsatility in the flow increases the phenomenon of platelet
attachment to the surface; however the platelet adhesion results did not show any
significant increase in platelet intensity for pulsatile flow rates.
One-way ANOVA and post hoc tests carried out for various phospholipid
modified Quatromers showed that the platelet adhesion results for PC, DMPC, and
DDPC modified Quatromer are statistically insignificant. DMPC and DDPC are the
saturated phospholipids and they have a compact bilayer as no kinks are present in their
hydrophobic tail and this helps them to provide better hydrophilic properties to the
surface. The saturation of their hydrocarbon tails decreases the water penetration and also
prevents them from suffering from oxidation reactions or double bond cleavage.
However, DDPC still may not be a good option for modification as the dissolving of
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DDPC with

Quatromer

solution took a long time and lot of stirring. The third

phospholipid, which showed excellent platelet adhesion, was PC which inspite having a
double bond in its structure showed good hemcompatibility properties. The reason for
this is that PC has a larger hydrophilic head when compared to the other phospholipids
and the presence of this larger phospholipid head improved its surface

modifying

properties. Another phospholipid, which showed good platelet adhesion results, was
DOPC, however this phospholipid has two double bonds in its tail structure and this may
result in increased oxidation to form free radicals or peroxides. EPC has shown to have
higher oxidation resistance due to the presence of ethanolamine in its structure however;
the platelet adhesion results were not that good. The last phospholipid i.e. DAPC has
eight double bonds in its structure and it is highly susceptible to cleavage of the double
bonds forming unstable peroxides in vivo. Also, DAPC did not showed good platelet
adhesion results and hence, it was ruled out.
One of the most important issues in deciding which phospholipid to consider for
modification of Quatromer was the cost of the phospholipids. Phospholipids are quite
expensive and there use may result in increased production cost of the biomedical
implant. Table 5.1 shows the prices of the six different phospholipids used in the
modification process of Quatromer. It can be observed that the price of DMPC is onethird when compared to the other phospholipids in consideration. Hence looking at the
different advantages of DMPC such as low platelet adhesion, high oxidation resistance,
stability of CH bonds, and low cost, it looks to be the most promising phospholipid for

Quatromer modification when compared to the others.
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Table 5.1 Prices for the various phospholipids used in modification of Quatromer

Material

Price ($)

Phosphatidylcholine (PC)

$26.00/25 mg

Ethanolaminephosphatidylcholine (EPC)

$37.86/25 mg

1, 2 -Dimyristoyl-rac-glycero-3-phosphocholine (DMPC)

$9.20/25 mg

1,2-Didodecanoyl-rac-glycero-3-phosphocholine (DDPC)
1,2-Dilinoleoyl-rac-glycero-3-phosphocholine (DOPC)

$42.30/25 mg
$23.00/25 mg

1,2-Diarachidonoyl-rac-glycero-3-phosphocholine

(DAPC

$101.~00/25 mg

On comparing the surface modification technique and phase mixing technique to
modify the Quatromer with phospholipid, the phase mixing technique would be the
choice due to its numerous advantages in imparting long-term hemocompatibility. The
various advantages such as homogenous or uniform distribution of phospholipid
throughout the Quatromer material, formation of bilayers, and passive migration of inside
phospholipid bilayers towards the surface on aging of the surface phospholipids, shows
3% phospholipid/Quatromer phase mixing technique to be a better choice for Quatromer
modification.
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CHAPTER

VI

CONCLUSIONS
6.0

Conclusion
The use of present prosthetic heart valves has been associated with incidence of

structure

failure,

calcification, thrombosis,

thromboembolism,

and

anticoagulant

complications. This requires the need to look for a new class of hybrid biomaterial, which
would have a combination of excellent material strength and durability as well as
superior hemocompatibility. It has been observed that the present mechanical valves,
possess the required material durability, however they fail when the surfaces comes in
contact with blood leading to thrombosis and anticoagulant complications. The other
type, bioprosthetic valves, has near native blood flow characteristics, yet they suffer from
material degradation due to the deposition of calcium on the leaflets. Thrombosis and
structural failure are clearly problems associated with the choice of material. The
polymer heart valves with a superior biomaterial have the potential to eliminate the
complications encountered in mechanical and bioprosthetic heart valves. A polymer
composite having high resistance to oxidation reactions and excellent blood compatibility
properties may help in the development of the next generation artificial heart valves. The

Quatromer modified with phospholipids has the potential to be a superior biomaterial for
artificial implants. The phospholipid modification would help to improve the blood
compatibility properties as well as the material properties of the Quatromer.
In this study the potential of a new Quatromer phospholipid composite was
evaluated to improve the long-term blood compatibility of a trileaflet heart valve
material.

This composite was prepared by mixing 3% phospholipid by weight with
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Quatromer and the hemodynamic and mechanical properties of the composite were
evaluated.

Six

different

saturated

and unsaturated

phospholipids

with

varying

hydrocarbon chain lengths were used to modify the Quatromer. The primary findings of
the study show that phospholipid modification tends to increase the wettability of the
highly hydrophobic

Quatromer surface. The surface analysis results show that

phospholipid modification of

Quatromer surface

decreases the contact angle significantly

and also leads to an increase in the carbonyl groups on the surface, which correlates, with
increased endothelial growth on the surface.

The improved surface properties of

phospholipid modified Quatromer are further supported by comparative platelet adhesion
tests performed on Quatromer and phospholipid modified Quatromer. The platelet
adhesion tests carried out using a parallel flow chamber showed that the phospholipids
are capable of reducing the platelet adhesion on the surface by ten times. The mechanical
tests performed on the phospholipids showed that the addition of phospholipids tend to
decrease the

modulus

of elasticity of the Quatromer, however in the polymer leaflets,

950 of the load is carried by the mesh and hence, a decrease in the elasticity of

Quatromer on

phospholipid addition should not be a problem. The platelet addition tests

showed that the DMPC proved to be the best phospholipid as it had higher oxidation
resistance,

significantly

low

platelet

adhesion,

high

wettability,

and

ordered

configuration. The phospholipid modification also helped in imparting secondary benefits
to the Quatromer material, such as reduced tackiness or surface friction, smooth and
homogeneous surface. The advantage of achieving reduced Quatromer tackiness is
important in efficient manufacturing of the leaflets.
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Based on the above findings, it can be concluded that the modification of
Quatromer with DMPC would provide promising results in improving the long-term
hemocompatibility of the polymer and increase its potential to be used in making
polymeric heart valves. Studies still need to be carried out to assess an optimum
concentration of phospholipid in the Quatromer material. Also, it is recommend that a

more

efficient way of fabricating DMPC modified leaflets may be devised, which would

prevent any denaturizing or reorientation of the functional groups on the surface. One of
the problems with fabrication of DMPC modified leaflets using compression molding
would be operation at high temperatures. It has been discussed earlier that high
temperatures tend to increase the disorderess of the bilayers in the phospholipid and
hence, an alternate fabrication technique should be developed to prevent change of
phospholipid properties at high temperatures.

Peeling tests for DMPC modified

Quatromer should be performed to determine adhesion force at the point of contact
between the stent and the leaflets. Another important step would be to carry out in vivo
pre-clinical testing of synthetic heart valves fabricated using this composite material. The
platelet adhesion tests for the Quatromer as well as the DMPC modified Quatromer has
been performed using in vitro controlled study with flat rectangular specimens, however,
in vivo studies may show different results for both as the study would have the specimens
in a leaflet shape (having curvatures). Hence, preclinical in vivo tests are required to
better evaluate DMPC modified Quatromer's potential in reducing platelet adhesion on
the surface.
Basically, it has been observed that the reduced thrombotic potential of the

Quatromer is due to the presence of phospholipids in the bulk material; however these
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phospholipids are susceptible to oxidation reactions over time. One of the possible ways
to overcome this shortcoming is to form a hemocompatible amphiphilic block polymer
where a highly hydrophobic polymer is linked with a highly hydrophilic polymer. Thus,
an amphiphilic block polymer i.e. poly (2-methacryloyloxyethyl phosphorylcholine
(MPC)-block-s

rene) can be fabricated, which would have the hydrophobic styrene

linked with the hydrophilic MPC polymer. This kind of amphiphilic polymer may
possess good blood compatibility properties, which

may last

over a long period of time.

Another, possible way to enhance the Quatromer material properties would be attaching a
hydrophilic PEG (polyethylene glycol)/phospholipid mixture, which may help to render
more oxidation resistance as well as a hemocompatible surface. Hence, with the optimum

material

properties and reliable fabrication process, a Quatromer heart valve with a

potential to mimic natural heart valve function and structure can be obtained.
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Protocols for
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specimen preparation

1.

Preparation of 20% Quatromer in toluene solution
a. Dry Quatromer pellets in oven at 70 0 C for 24 hours.
b.

Take a 250 mL glass jar with black top and Teflon lid liner with a

magnetic

stirrer in it.
c.

Add to the glass bottle:
i.

Quatromer 40 g

ii.

Toluene 160 g

iii.

Mix with or without heat (70®C) until dissolved.

iv.

Remove from mixer and replace lid.

d. Label bottle with 20% Quatromer in toluene and date mixed.

2.

Preparation of Dogbone Specimens
a. Clean the stainless steel base plate, stainless steel rectangular blocks, and
brass gaskets with alcohol pads.
b. Dry the components of the plate assembly with Kimwipes.
c. Put the brass gaskets on the base plate and the stainless steel rectangular
blocks on the brass gaskets, and screw them together.
d. In the hood, wearing a respirator and latex gloves, fill a graduated pipette with
20%

e.

Quatromer solution in toluene prepared using the above method.

Pour 5.0mL of the 20%

Quatromer

solution in each of the rectangular cavity

to achieve a specimen thickness of approximately 0.3mm.
f. Prepare sure that the liquid in the cavity has no bubbles in it.
g. Place the plate assembly horizontally in the oven at 70 C, and it to dry for 4
hours.
h. On removal from the oven, allow the dish to cool to room temperature
i.

Cut rectangular samples from each of the cavity using a blade.

j.

Place the specimen on the dogbone-cutter, and punch the dogbone shape out
using a hammer.

number the
k. Apply Johnson's baby powder to the Dogbone specimens, and
specimens.
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1.

Place them in a ziplock bag and label them 20% Quatromer with date of
manufacture, specimen numbers contained, and volume of solution used to
prepare the specimen.

3.

Preparation of 3% phospholipid/Quatromer composite
a. Take a 10 mL glass jar with black top and Teflon lid liner with a magnetic
stirrer in it.

b. To prepare 3% phospholipd/Quatromer composite, add to the glass bottle:
i.

20% Quatromer in Toluene (1 g Quatromer and 4 g Toluene) 5 g

Phospholipid 30 mg
ii.

Mix until dissolved.
Remove from mixer and replace lid.

iii.

c. Label bottle with 3% phospholipid/Quatromer mixture and date mixed.

4.

Preparation of phospholipid surface modified Quatromer:
a. Take a 50 mL glass jar with black top and Teflon lid liner with a magnetic
stirrerin it.
b. To prepare 20% phospholipd/Quatromer, add to the glass bottle:

c.

i.

20% Quatromer in Toluene (5 g Quatromer and 20 g Toluene) 25 g

ii.

Phospholipid 1 g

iii.

Mix until dissolved.

iv.

Remove from mixer and replace lid.

Label bottle with 20% phospholipid/Quatromer mixture and date mixed.

d. Take another 50 mL glass jar with a magnetic stirrer.
strips prepared using plate assembly in the
0
20% phospholipid/Quatromer mixture at 50 C for 1 hour.

e. Dip rectangular 20%

Quatromer
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APPENDIX B - Protocols for Mixing Chemical Solutions

110

ieparin
Ingredients:
0

50 mg of heparin sodium

1l66.5 mL of 0.9% NaCi
Mix together and pass through a 22-pm membrane filter.

stored at 4*C.

Solution should be

Using 5 mL of Heparin solution corresponds to 270 units of

Heparin

Mepcrine
Ingredients:
*

4.7 mg of Mepacrine

*

1 mL of Water

Mix 4.7 mg of Mepacrine in 1 mL of water to prepare a stock solution of 10 mM
Mepacrine in water and store it at 4 C in a foil covered tube.
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APPENDIX C - Protocol for Nlepacrine Labeling
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Sringe Preparation for Blood

Withdrawal

1. Label three 60 ml syringes as Syringe 1 - Heparin, Syringe 2 - Heparin, and Syringe
3- Heparin.
2. Extract 5 ml of Heparin solution (270 units) into Syringe 2-Heparin, Syringe 2Heparin, and Syringe 3-Heparin.
3.

Give all three syringes to the phlebotomist for blood withdrawal.

4. Collect 50 ml of blood into all the three syringes filling to a total of 55 ml.
5.

Place syringes on rocker

6. Transfer the blood from the three syringes into a 500 mL plastic bottle.
7. Cover the bottle with Aluminum foil.
8. Take the 10mM Mepacrine solution and add 150pL of Mepacrine to 150 mL of
blood.
9. Close the Mepacrine tube and the Blood containing bottle quickly.
10. Invert the bottle gently a couple of times to mix the platelets with Mepacrine.
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APPENDIX D - AutoCAD Drawings for
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IRB RESEARCH PROPOSAL

1.

Research Objectives

Heart valve prostheses have been used successfully since 1960; however, the two
classes

of prostheses

that are

commercially

available

today

(mechanical

and

bioprosthetic) have their associated shortcomings. The research outlined in this proposal
aims to lead to the development of a third class of valves, polymer trileaflet valves, that
combine the advantages of the mechanical and bioprosthetic valves for a better
alternative for heart valve replacement.

The overall project aims to determine an

appropriate material, an appropriate design, and a repeatable and reliable manufacturing
process for the valve. The polymer chosen for the development of this valve (SIBS) has
established biostability, but the thrombogenic potential of the material is unknown. It is
the intention of this particular research study to compare the thrombogenic potential of
SIBS, polyurethane, and porcine or pericardial valve material by measuring platelet
deposition under controlled in vitro flow conditions.

Blood samples obtained from

human volunteers will be pumped through chambers containing test materials, and the
deposition of platelets on the materials will be measured and compared.

2.

Subject Recruitment

Normal, healthy, non-smoking subjects who are over 18 and have not consumed
alcohol, aspirin, or vitamin E within the last 24 hrs, and who are not pregnant will be
recruited from the local student population. Approximately twenty subjects will be
recruited.

3.

Benefits

(a)

No benefits to the subject.

(b)

Importance of knowledge to be gained.
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The results of this research will provide data regarding the feasibility of the new

SIBS material as a potential material for use in artificial heart valves. If this research is
successful, artificial heart valve recipients will live longer and maintain a higher quality
of life by the elimination of repeat surgeries or the use of anticoagulant therapy.

4.

Risks to Subjects

The study requires the collection of blood samples from volunteers.

For each

experiment, approximately 150 mliters of blood will be collected from the subject by
venipuncture using sterile equipment. Venipuncture presents minimal risk of infection,
discomfort, and possible bruising. Care will be taken to ensure that an individual subject
will not be sampled more than twice in one week and in an amount not exceeding 450
mliters in an eight-week period.

The procedure will be performed at FIU's

Cardiovascular Engineering Center by a licensed phlebotomist. A screening procedure,
by means of a survey, will determine the health of the patient in terms of anemia, HIV,
and Hepatitis B status. The patient will be provided a place to lie comfortably during the
venipuncture procedure, and juice and cookies will be provided following the procedure.
All staff in FlU's Cardiovascular Engineering Center that will be handling the blood
will be vaccinated against Hepatitis B, and they will be required to wear latex gloves and
lab coats at all times. The rooms are well labeled to caution against biohazards.

5.

Informed Consent

Written informed consent will be obtained from each subject before each collection
of material. (see enclosed informed consent form).

6.

Confidentiality of Data

123

Data obtained from the experiments will be reported as averages and will not
disclose individual information. The data obtained will include platelet counts, red blood
cell counts, and platelet deposition counts. In addition, the data will be coded and the key
to the code will be kept in a locked cabinet with access only available to the PI. All
health surveys and informed consent documents will also be kept in the locked cabinet;
however, none of the data obtained is expected to be detrimental to the subject.

7.

Methods and Procedures:

Following a screening procedure

to determine

overall health of a subject,

approximately 150 mliters of blood will be collected from each subject by venipuncture
using sterile equipment.

This sample of blood will then be used in the experiments

described in #1 above. Care will be taken to ensure that an individual subject will not be
sampled more than twice in one week and in an amount not exceeding 450 milliliters in
an eight-week period.

The procedure will be performed at FIU's Cardiovascular

Engineering Center by a licensed phlebotomist.

8.

Stimulus Materials

None.
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iJFIW
CONSENT TO PARTICIPATE IN A RESEARCH STUDY
Title: a Novel Polymer Trileaflet Heart Valve
You are being asked to be in a research study to be conducted at Florida International University during the
2003-2004 academic year. The investigator of this study is Tejas Choksi and she is a student at Florida
International University (FIU). The study will include 20 subjects who are students studying at FIU. Your
participation would require 10 minutes of your time. We are looking to gain further understanding of the
thrombogenic potential of SIBS (polymer used for trileaflet heart valve prosthesis) material modified with
various surfactants by measuring platelet deposition under controlled in vitro flow conditions.
If you decide to be a part pf the study we will tell you what day and time to come to the Cardiovascular
Engineering (CVEC) lab. The procedures for drawing blood will be as follows: 150 milliters of blood will
be collected by venipuncture from my forearm, by a licensed phlebotomist, into three 50 cc syringes
containing heparin as an anticoagulant. This blood sample will then be used in blood flow experiments
designed to measure platelet deposition. The venipuncture procedure presents a minimal risk of infection,
discomfort and possible bruising. Incase you get hurt or upset a licensed phlebotomist would be there to
provide you with the necessary help needed.
There is no cost or payment to you as a subject. You will not get any direct benefit from being in the study.
However, your help will give us information about the thrombogenic potential of SIBS polymer, which
would serve as a potential material in the development of a novel trileaflet heart valve used to
cardiovascular disorders. You will get juice and cookies as a token for being in the study.
Your data regarding the blood sample (platelet count, red blood cell count, and platelet deposition count)
will be kept confidential. The data will be coded and the key to the code will be kept in a locked cabinet
with access only available to the PI. You may ask questions about the study at any time and any questions
will be answered to your satisfaction. You may choose not to participate in this research project at any time
with no negative consequences. You may also choose to stop your participation before the procedure
finishes. Even if you do not finish the procedure you will get the juice and cookies.
If you would like more information about this research after you are done, you can contact Dr. Richard T.
Schoephoerster, Principal Investigator of this research or me at 305-348-3722. If you would like to talk
with someone regarding the rights of research subjects, you should contact Dr. Bernard Gerstman,

Chairperson of the FIU Institutional Review Board at 305-348-3115 or 305-348-2494
Your signature below indicates that all questions have been answered to your liking. Your are aware of
your rights and you would like to be in the study.

Signature of Participant

Printed Name

Date

I have explained the research procedure, subject rights, and answered questions asked by the participant. I
have offered him/her a copy of this informed consent form.

Signature of Witness

Printed Name
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Date

APPENDIX F - Matlab Program
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function bkgndcorrect(ref,actdata,fileout,strp)

% This

function is used to background correct TIF images

from the stent project
% 1st input - reference inlet TIF file
% 2nd input - actual data TIF file
% 3rd input - output file name for storage
% 4th input - number of strips of each frame
% For 4th input - enter 1 if data is to be regressed on a line by line basis
% For 4th input - enter 2 if data is to be regressed on the average from 252 lines (504/2)
% Input reference file read
A=imread(ref,'tif);
A=double(A);
[M,N]=size(A);
n=1:l:N;
m=floor(M/strp);
% Average of intensity from input reference file
tot=sum(sum(A));
avg=tot/(M*N);
% Actual data file read
B=imread(actdata,'tif);
%

B=double(B);
% Average data of the required number of rows (based on number of strips as input)
datalnp=zeros(M,N);
dataOut=zeros(M,N);
if strp==1
datalnp=A;
dataOut=B;
else
ind=1;
for i=1:m:M

j=i
while (j<=(i+m-1) & (i+m-1)<=M)
datalnp(ind,:)=datalnp(ind,:)+A(j,:);
dataOut(ind,:)=dataOut(ind,:)+B(j,:);

j=j+1;
end
dataInp(ind,:)=dataInp(ind,:)/m;
dataOut(ind,:)=dataOut(ind,:)/m;
ind=ind+1;
end
end

[F,G]=size(datalnp);

% Regressing 4th order polynomial to data from input reference file
% across all rows
for i=1:F
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dataO=mean(datalnp);

coeff(i,:)=polyval(polyfit(n,dataO,4),n);
end
00 Background correction: (data/ref)*avg
for i=1:F

for j=1:G
C(i,j)=dataOut(ij)*avg/coeff(i,j);
end
end
Cavg=mean(C);
Cavg=Cavg';
% Write background corrected data into output file
fid=fopen(fileout,'w');
for i=1:size(Cavg)
count=fprintf(fid,'%8.5fn',Cavg(i));
end
fclose(fid);
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APPENDIX G - Statistics
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Table FL. One-way ANOVA test for Sylgard (control), Quatromer, and different
phospholipid modified Quatromers at different shear rates for 5 1 mn time interval
ANOVA

TIMES

Between Groups
Within Groups

Sum of
Squares
21601.947
331.943

Total

21933.890

Mean Square
553.896

df
39
360

F
600.714

Sig.
.000

.922

399

Table F2. One-way ANOVA test for Sylgard (control), Quatromer, and different
phospholipid modified Quatromers at different shear rates for 15 1 min time interval

ANOVA
TIME15

Sum of
Squares

df

Mean Square

Between Groups
Within Groups

52881.141
582.518

39
360

Total

53463.659

399

1355.927

F

837.972

Sig.
.000

1.618

Table F3. One-way ANOVA test for Sylgard (control), Quatromer, and different
phospholipid modified Quatromers at different shear rates for 25 1 min time interval
ANOVA
TIME25

Between Groups
Within Groups
Total

Sum of
Squares
107145.4
609.666
107755.0

Mean Square
2747.317
1.694

df
39
360
399
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F
1622257

Sig.
.000

Table F4. Tukey post hoc test for Sylgard (control), Quatromer, and different
phospholipid modified Quatromers at different shear rates for 5 1 min time interval

Tukey HSB
MATERIA
O0PC+0-LS
DMPC+Q-HP

1

N
10

2.4

10

276

2.76

10

2.88

288

284

2.84

DMPC+Q-LS

10

PC+Q-MP

10
10
10
10
10
10
10

312
3.13
3.16
3.15
3.18
3.46
4,16

3.12 3.12

DDPC+Q-MP

10
10
10
10
10
10

DDPC+Q-HP
DMP C+Q- H S
DOPC+0-HS
DMPC+Q-MS
PC+Q-LS
DDPC+0-HS

DDPC+Q-MS

DMP C+Q-MP
PC+Q-MS

DOPC+Q-MS
DOPC+Q-LS
DOPC+Q-HP
DOPC+Q-LS
PC+0-HP
PC+Q-H S

DAPC+Q-LS
DAPC+Q-MS
EPC+Q-MP
DAPC+Q-MP
EPC+0-HS
EPC+Q-LS
EPC+Q-HP
EPC+Q-MS

DAPC+Q-HS
DAPC+Q-HP
S-MP
S-MS
S-LS
S-HS
0- LS

Q-MP

10

10
10
10
10
10
10
10
10
10
10
10
10
10
10

3.13
3.16
3.15
3.18
3.46
4.16
4.23
4.34

3

4

5

6

Subset

8

7

for

alpha

9

= .05

1i

1

12

13

14

3.46

4.16
4.23
4.34
4.77

3,46
4.16
423
4.34
4.77
4.92

5.12
5.14

4.16
4.23
4.34
477
4.92
6.12
5.14
5.52
5.68

4.34
477
4.92
5.12
5.14
5.52
5.68 5.68
5.97 5.97 5.97
7.24 7,24
7.39

7.24
7.39

7.58

7.58

7,78
8.28
8.52
8.59
8.67

8.59 8.59
8.67 8.67
927 9.27
10.24
12.21
13.38
15.44
19.42
19.71

10

0-HP

10

Q-HS

10

17

8.52 8.52

10

Q-MS

16

7.78
8.28

10

S-HP

15

3.13
3.16
3.16
3.18

10

10
10

Sig.

2

1.92
2.14
3.43
27.05

.056 .116 .065 .053 .161 .070 .124
Wans for groups in homogeneous subsets are displayed.
a. Uses Harmonic Mean Sample Size = 10.000.

.087
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.244 .194

.065

.74

1.000 1.000 .171

30.43
1.000 1.000

Table F5. Tukey post hoc test for Sylgard (control), Quatromer, and different
phospholipid modified Quatromers at different shear rates for 15 1 min time interval
TIM E20
Tukey HST

MTER
H
1
OMPC+0-HS 10 3.51
DDPC+-LS 10 3. 78

DDPC+Q-HP

3

OMPC+Q-LS

10
10

3. 2
411

PC+Q-LS

10

4.78

4.78

D OP C+Q- H S 10
DO PC+Q-MP 10
DMPC+Q-MS 10
O D P C+Q- H S 10

4.3

4.52
4.01

4.52
4.01

4.52
4.61

4.74

4.74 4.74
4,73 4178

PC+0-MP
0MPC+Q-MP
D PC+QHP
DPC+Q-MS
PC+Q-HP

4.73

4

5

Subset

7

8

for alphas
9

10

8.98 8.98 8.98

DAPC+Q-LS

9.21

EPC+Q-HS

10
10
10
10

EPC+Q-MS

10

EPC+Q-LS
EPC+0-HP
DAPC+Q-HP

S-MS
S-LS
S-MP
0-MS

10
10
10
10
10
10
10
10

0- LS

10

-MP

10

S-HS

S HP

10
10

Q-HS

10

DOPC+Q-LS
PC+Q-H S

DAPC+Q-MP
DAPC+0-MS

DAPC+Q-HS

13

14

15

16

17

18

4.61
4.74 4.74
4.70 4.70

EPC+Q-MP

PC+Q-MS

___

12

4.52
4.61

DOPC+Q-HP

DOPC+Q-LS
DDPC+Q-MS

.05
11

4.1

10
10
10
10
10
10
10
10
10
10
10

4.83
4.89
5.31
5.52

10

4.83
4,89
5.31
5.52
6.33

4.83 4.83
4.89 4.89
5.31 531
5.52 5.52

4.83
4,89
5.31 5.31
5.52 5.52

6.33 6.33 6.33 6.33
6.53 6.53 6.53 6.53
6.61 6.61 6.61
6.64 6.64 6.64
6.76 6.76 6.76
7.34 7.34 7.34
7.37 7.37 7.37
9.21
9.80
10.80
10.87
10.99

9.80
10.80
10.87
10.99
11.72
14.22
14.61
15.80
19.73
21,73
4.73
28.34
30.30 30.30
31.22

6.73
39.73
40.28

Q-HP

10
.164 .053 .060 .094 .080 128
Sig.
Means for groups in homogeneous subsets are di splayed
a. Uses Harrmonic ian Sampie Size= 10.00.

.053 .301

132.

164

245

705

2.54
.171 1.000 .206 1.000 1.000 1.000 1.000

Table F6. Tukey post hoc test for Sylgard (control), Quatromer, and different
phospholipid modified Quatromers at different shear rates for 25 1 mi time interval
TIME30
Tukey HSt3
MATERIAL
00PC+Q-HP

DDPC+Q-LS
DMPC+Q-HS

N

10

DOPC+Q-HP

10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10

EPC+Q-MP

10

DAPC+Q-LS

10

DAPC+Q-MP

10

DAPC+Q-MS

10

EPC+0-HS
EPC+0-LS
EPC+Q-MS
EPC+Q-HP

10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10

DMPC+0-LS

DDPC+Q-HS
DDPC+0-MP
DMPC+Q-MP
PC+Q-MP
PC+Q-LS
DMPC+Q-MS

DMPC+Q-HP

DOPC+Q-MS
DOPC+Q-HS

PC+Q-MS

DOPC+0-LS
D0PC+Q-LS
DDPC+Q-MS
PC+-H S
PC+Q-HP

DAPC+0-HP
DAPC+Q-HS
S-MP
S-MS

Q-MP
S-LS
Q-MS

Q-LS

S-HP
0-HP
Q-HS
S-HS

2
4.19
4.43
4.66
4.77

512
5.23
5.67
6.15
6.24
6.31

3

4

5

6

8

Subset for alpha = .05
0
10
11
12

13

14

15

16

17

18

10

20

443
4.66
4.77 4.77
512 512 5.12
5.23 5.23 5.23

567
6.15
6.24
6.31

567
6.15
6.24
6.31

5.67
6.15
6.24
6.31

5.67
6.15 6.15
6.24 6.24
6.31 6.31

6.69 6.69 6.69 6.69

6.69 6.69

6.72 6.72 6.72 6.72 6.72
6.98 6.98 6.98 6.98 6.98
7.14 7.14
7.18 7.18
7.58
7.62
7.83

7.14
7.18
7.58
7.62
7.83

7.14
7.18
7.58
7.62
7.83
8.05 8.05
8.92

.120 .051 .075 .161 .098 .304
Means for groups in homogeneous subsets are displayed.
a. Uses Harmonic Mean Sample Size = 10.00.
ig.

7

8.05
8.92
10.12

8.92
10.12 10.12
10.72 10.72 10,72
11.61 11.61 11.61
12.52 12.52 12.62
12.73 12.73 12.73
13.34 13.34
14.32
16,83
17.74
18.52
37.17
39.58
39.67
41.13

1.13
2.13
2.68
50.86

51.0451.04
53.18

53.18

53.99
.075

.153

.446
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843

.211

.559

.02
.4

1.000

.789

.789 1.000 .109

1.000

